1
|
Wang W, Rui H, Yu L, Jin N, Liu W, Guo C, Cheng Y, Lou Y. Four-Chlorophenoxyacetic Acid Treatment Induces the Defense Resistance of Rice to White-Backed Planthopper Sogatella furcifera. Int J Mol Sci 2023; 24:15722. [PMID: 37958711 PMCID: PMC10648403 DOI: 10.3390/ijms242115722] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2023] [Revised: 10/27/2023] [Accepted: 10/27/2023] [Indexed: 11/15/2023] Open
Abstract
Chemical elicitors can increase plant defense against herbivorous insects and pathogens. The use of synthetic chemical elicitors is likely to be an alternative to traditional pesticides for crop pest control. However, only a few synthetic chemicals are reported to protect plants by regulating signaling pathways, increasing the levels of defense metabolites and interfering with insect feeding. Here, we found that the exogenous application of a phenoxycarboxylic compound, 4-chlorophenoxyacetic acid (4-CPA), can induce chemical defenses to protect rice plants from white-backed planthoppers (WBPH, Sogatella furcifera). Four-CPA was rapidly taken up by plant roots and degraded to 4-chlorophenol (4-CP). Four-CPA treatment modulated the activity of peroxidase (POD) and directly induced the deposition of lignin-like polymers using hydrogen peroxide (H2O2) as the electron acceptor. The polymers, which are thought to prevent the planthopper's stylet from reaching the phloem, were broken down by WBPH nymphs. Meanwhile, 4-CPA increased the levels of flavonoids and phenolamines (PAs). The increased flavonoids and PAs, together with the degradation product of the polymers, avoided nymphal feeding and prolonged the nymphal period for 1 day. These results indicate that 4-CPA has the potential to be used as a chemical elicitor to protect rice from planthoppers. Moreover, these findings also open a pathway for molecule structure design of phenoxycarboxylic compounds as chemical elicitors.
Collapse
Affiliation(s)
- Wanwan Wang
- Jiangsu Key Laboratory of Chiral Pharmaceuticals Biosynthesis, Taizhou University, Taizhou 225300, China; (H.R.); (L.Y.); (W.L.); (C.G.); (Y.C.)
- State Key Laboratory of Rice Biology & Ministry of Agriculture Key Lab of Molecular Biology of Crop Pathogens and Insects, Institute of Insect Sciences, Zhejiang University, Hangzhou 310058, China;
| | - Haiyun Rui
- Jiangsu Key Laboratory of Chiral Pharmaceuticals Biosynthesis, Taizhou University, Taizhou 225300, China; (H.R.); (L.Y.); (W.L.); (C.G.); (Y.C.)
| | - Lei Yu
- Jiangsu Key Laboratory of Chiral Pharmaceuticals Biosynthesis, Taizhou University, Taizhou 225300, China; (H.R.); (L.Y.); (W.L.); (C.G.); (Y.C.)
| | - Nuo Jin
- State Key Laboratory of Rice Biology & Ministry of Agriculture Key Lab of Molecular Biology of Crop Pathogens and Insects, Institute of Insect Sciences, Zhejiang University, Hangzhou 310058, China;
| | - Wan Liu
- Jiangsu Key Laboratory of Chiral Pharmaceuticals Biosynthesis, Taizhou University, Taizhou 225300, China; (H.R.); (L.Y.); (W.L.); (C.G.); (Y.C.)
| | - Chen Guo
- Jiangsu Key Laboratory of Chiral Pharmaceuticals Biosynthesis, Taizhou University, Taizhou 225300, China; (H.R.); (L.Y.); (W.L.); (C.G.); (Y.C.)
| | - Yumeng Cheng
- Jiangsu Key Laboratory of Chiral Pharmaceuticals Biosynthesis, Taizhou University, Taizhou 225300, China; (H.R.); (L.Y.); (W.L.); (C.G.); (Y.C.)
| | - Yonggen Lou
- State Key Laboratory of Rice Biology & Ministry of Agriculture Key Lab of Molecular Biology of Crop Pathogens and Insects, Institute of Insect Sciences, Zhejiang University, Hangzhou 310058, China;
| |
Collapse
|
2
|
Zhang J, Lu J, Zheng Z, Lu J, Wang A, Wang J, Chen J, Rui H, Chen C, Chen G. Discovery of D3S-001, a highly potent and CNS-penetrant inhibitor of KRAS G12C with rapid and sustained target engagement kinetics. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)00998-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
3
|
Liang J, Fan M, Wu W, Wu M, Cai W, Xinxing G, Huang T, Rui H. Encapsulation of Sandwich POM in MIL-101 as Efficient Oxidative Desulfurization Catalyst of DBT. Catal Letters 2022. [DOI: 10.1007/s10562-022-04057-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
4
|
Zhang X, Li X, Tang L, Peng Y, Qian M, Guo Y, Rui H, Zhang F, Hu Z, Chen Y, Xia Y, Shen Z. The root iron transporter 1 governs cadmium uptake in Vicia sativa roots. J Hazard Mater 2020; 398:122873. [PMID: 32768815 DOI: 10.1016/j.jhazmat.2020.122873] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/28/2019] [Revised: 04/28/2020] [Accepted: 04/29/2020] [Indexed: 06/11/2023]
Abstract
Cadmium is a non-essential element for plants and that inhibits plant growth and development. The Zhangye Mawan (ZM) variety of Vicia sativa is more sensitive to Cd toxicity than that Lanjian 3# (L3) variety, but the underlying mechanism is not fully understood. Here, we demonstrated that ZM showed higher Cd accumulation than L3 based on root Cd content and Cd fluorescence intensity in root protoplasts. VsRIT1, a member of the ZIP (ZRT/IRT-like protein) family, showed expression levels in ZM roots 8-fold higher than those in L3 roots under Cd exposure. VsRIT1 expression increased Cd transport and accumulation in Arabidopsis and yeast. These suggests that VsRIT1 participates in Cd uptake by V. sativa roots. Furthermore, ZM root tips have a higher capacity for transient Cd influx than L3 roots when exposed to Cd alone or Cd and iron (Fe) together, owing to the higher VsRIT1 expression in ZM. Our findings also imply that Cd may compete with Fe or/and zinc (Zn) for uptake via VsRIT1 in V. sativa or yeast.
Collapse
Affiliation(s)
- Xingxing Zhang
- College of Life Sciences, Nanjing Agricultural University, Nanjing, 210095, China; Guangdong Engineering Research Center for Pesticide & Fertilizer, Guangdong Bioengineering Institute (Guangzhou Sugarcane Industry Research Institute), Guangzhou, 510316, China
| | - Xin Li
- College of Life Sciences, Nanjing Agricultural University, Nanjing, 210095, China
| | - Ling Tang
- College of Life Sciences, Nanjing Agricultural University, Nanjing, 210095, China
| | - Yizhe Peng
- College of Resources & Environment, Hunan Agricultural University, Changsha, 410128, China
| | - Meng Qian
- College of Life Sciences, Nanjing Agricultural University, Nanjing, 210095, China
| | - Yafang Guo
- College of Life Sciences, Nanjing Agricultural University, Nanjing, 210095, China
| | - Haiyun Rui
- Taizhou University, Taizhou, 225300, China
| | - Fenqin Zhang
- College of Agriculture and Biotechnology, Hexi University, Zhangye, 734000, China
| | - Zhubing Hu
- Center for Multi-Omics Research, Key Laboratory of Plant Stress Biology, School of Life Sciences, Henan University, Kaifeng, 475004, China
| | - Yahua Chen
- College of Life Sciences, Nanjing Agricultural University, Nanjing, 210095, China; Jiangsu Collaborative Innovation Center for Solid Organic Waste Resource, Nanjing, 210095, China
| | - Yan Xia
- College of Life Sciences, Nanjing Agricultural University, Nanjing, 210095, China; Jiangsu Collaborative Innovation Center for Solid Organic Waste Resource, Nanjing, 210095, China.
| | - Zhenguo Shen
- College of Life Sciences, Nanjing Agricultural University, Nanjing, 210095, China; Jiangsu Collaborative Innovation Center for Solid Organic Waste Resource, Nanjing, 210095, China.
| |
Collapse
|
5
|
Lu C, Li L, Rui H, Lin C, Hao S, Hu C, Wang Y, Chen H, Yong H. P2.14-25 Lorlatinib Induced Protective Autophagy via the AKT–mTOR Pathway in ALK- Rearrangement Lung Cancer Cells. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1810] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
6
|
Yong H, Rui H. P1.03-27 Aspirin Overcomes Acquired Resistance to Osimertinib in Human Lung Cancer Cells via Bim-Dependent Apoptosis Induction. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.879] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
7
|
Schlaak R, Frei A, Schottstaedt A, Liu Q, Fish B, Gasparetti T, Harmann L, Sun Y, Rui H, Flister M, Medhora M, Strande J, Bergom C. Identification of Pathways and Genetic Variants Important for Radiation-Induced Cardiotoxicity Using Genetic Mapping. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.311] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
8
|
Wang YH, Jin X, Rui H, Liu T, Hou J. Erratum to: Cold Temperature Regulation of Zoospore Release in Phytophthora sojae: The Genes That Differentially Expressed by Cold Temperature. RUSS J GENET+ 2019. [DOI: 10.1134/s1022795419010162] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
9
|
Wang Y, Jin X, Rui H, Liu T, Hou J. Cold Temperature Regulation of Zoospore Release in Phytophthora sojae: The Genes That Differentially Expressed by Cold Temperature. RUSS J GENET+ 2018. [DOI: 10.1134/s1022795418060133] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
10
|
Praveen Kumar A, Kovatich AJ, Biancotto A, Cheung F, Davidson-Moncada JK, Kvecher L, Liu J, Ru Y, Kovatich AW, Deyarmin B, Fantacone-Campbell JL, Hooke JA, Raj Kumar PK, Rui H, Hu H, Shriver CD. Abstract P4-09-14: Analysis of breast cancer recurrence using gene set enrichment analysis. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p4-09-14] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Even after successful treatment of primary breast tumors, there is a continued risk of recurrence. The risk varies between subtypes and there are ongoing efforts that aim to improve prediction of such risks for individual patients. Detection of subclinical metastases might be achieved by biomarkers in blood. In this study, we profiled protein expression in blood plasma from patients with known clinical outcome (recurrence vs no recurrence) to identify prognostic markers of breast cancer recurrence.
Methods: The subjects and specimens were made available through the Clinical Breast Care Project using IRB-approved protocols. We analyzed blood plasma samples taken at the time of diagnosis from consented patients who subsequently relapsed (33 cases) as well as those with no disease recurrence (31 controls). Based on hormone receptor and lymph node status the samples were grouped as: ER-/HER2- (17 cases/15 controls), ER+/LN+ (10/10) and ER+/LN- (6/6). We used aptamer-based SOMAscan assay platform to study the expression of 1252 proteins. We analyzed the protein expression data by using their coding genes in order to apply the Gene Set Enrichment Analysis method (GSEA v.2, Broad Institute). Pathway databases of KEGG, REACTOME, BIOCARTA and C4 collection were used. Significant gene sets were called at 5% FDR, and overlaps and low coverage gene sets (Tags <70%) were removed. Statistical analysis and clustering were done using R.
Results: Unsupervised clustering showed some difference in signal in the ER+/LN- group. Even though there was a lack of significantly differentiated proteins between the cases and controls of this group, many significant gene sets were identified. After applying the cutoff filters and removing the overlaps, there were 5 gene sets enriched with the pathway collection, involved in B-cell receptor signaling, mRNA metabolism, tight junction and SCF-KIT signaling. Similarly, 9 gene sets from the MORF compendium were differentially expressed with the C4 collection and included neighborhood genes of NME2, ACTG1, EIF3S2, AP2M1, DAP3, UBE2I, NPM1, AATF and NPM1. In contrast, neither differentially expressed proteins nor gene sets were identified from the ER+/LN+ and ER-/HER2- groups. Since the sample size of the ER+/LN- group was small, we conducted a similar analysis by randomly choosing 6 case and control samples in the other two groups respectively. There were still no differentially expressed proteins or gene sets identified above the specified cutoff parameters.
Conclusion: Using plasma protein expression data we identified underlying gene sets differentially expressed between ER+/LN- patients who had cancer recurrence and no recurrence. Many genes in these sets were already known biomarkers (e.g. PTEN, AKT1, STAT3, SET etc.). These results can be used for understanding patterns of recurrence in different cancer subtypes. Further research is needed to estimate the clinical significance of these gene products.
The views expressed in this article are those of the author and do not reflect the official policy of the Department of Army/Navy/Air Force, the Department of Defense, or U.S. Government.
Citation Format: Praveen Kumar A, Kovatich AJ, Biancotto A, Cheung F, Davidson-Moncada JK, Kvecher L, Liu J, Ru Y, Kovatich AW, Deyarmin B, Fantacone-Campbell JL, Hooke JA, Raj Kumar PK, Rui H, Hu H, Shriver CD. Analysis of breast cancer recurrence using gene set enrichment analysis [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P4-09-14.
Collapse
Affiliation(s)
- A Praveen Kumar
- Chan Soon-Shiong Institute of Molecular Medicine at Windber, Windber, PA; Clinical Breast Care Project, Murtha Cancer Center, Uniformed Services University / Walter Reed National Military Medical Center, Bethesda, MD; National Institutes of Health, Bethesda, MD; MacroGenics, Inc, Rockville, MD; MDR Global Systems, Windber, PA; Medical College of Wisconsin, Milwaukee, WI; Murtha Cancer Center, Uniformed Services University / Walter Reed National Military Medical Center, Bethesda, MD
| | - AJ Kovatich
- Chan Soon-Shiong Institute of Molecular Medicine at Windber, Windber, PA; Clinical Breast Care Project, Murtha Cancer Center, Uniformed Services University / Walter Reed National Military Medical Center, Bethesda, MD; National Institutes of Health, Bethesda, MD; MacroGenics, Inc, Rockville, MD; MDR Global Systems, Windber, PA; Medical College of Wisconsin, Milwaukee, WI; Murtha Cancer Center, Uniformed Services University / Walter Reed National Military Medical Center, Bethesda, MD
| | - A Biancotto
- Chan Soon-Shiong Institute of Molecular Medicine at Windber, Windber, PA; Clinical Breast Care Project, Murtha Cancer Center, Uniformed Services University / Walter Reed National Military Medical Center, Bethesda, MD; National Institutes of Health, Bethesda, MD; MacroGenics, Inc, Rockville, MD; MDR Global Systems, Windber, PA; Medical College of Wisconsin, Milwaukee, WI; Murtha Cancer Center, Uniformed Services University / Walter Reed National Military Medical Center, Bethesda, MD
| | - F Cheung
- Chan Soon-Shiong Institute of Molecular Medicine at Windber, Windber, PA; Clinical Breast Care Project, Murtha Cancer Center, Uniformed Services University / Walter Reed National Military Medical Center, Bethesda, MD; National Institutes of Health, Bethesda, MD; MacroGenics, Inc, Rockville, MD; MDR Global Systems, Windber, PA; Medical College of Wisconsin, Milwaukee, WI; Murtha Cancer Center, Uniformed Services University / Walter Reed National Military Medical Center, Bethesda, MD
| | - JK Davidson-Moncada
- Chan Soon-Shiong Institute of Molecular Medicine at Windber, Windber, PA; Clinical Breast Care Project, Murtha Cancer Center, Uniformed Services University / Walter Reed National Military Medical Center, Bethesda, MD; National Institutes of Health, Bethesda, MD; MacroGenics, Inc, Rockville, MD; MDR Global Systems, Windber, PA; Medical College of Wisconsin, Milwaukee, WI; Murtha Cancer Center, Uniformed Services University / Walter Reed National Military Medical Center, Bethesda, MD
| | - L Kvecher
- Chan Soon-Shiong Institute of Molecular Medicine at Windber, Windber, PA; Clinical Breast Care Project, Murtha Cancer Center, Uniformed Services University / Walter Reed National Military Medical Center, Bethesda, MD; National Institutes of Health, Bethesda, MD; MacroGenics, Inc, Rockville, MD; MDR Global Systems, Windber, PA; Medical College of Wisconsin, Milwaukee, WI; Murtha Cancer Center, Uniformed Services University / Walter Reed National Military Medical Center, Bethesda, MD
| | - J Liu
- Chan Soon-Shiong Institute of Molecular Medicine at Windber, Windber, PA; Clinical Breast Care Project, Murtha Cancer Center, Uniformed Services University / Walter Reed National Military Medical Center, Bethesda, MD; National Institutes of Health, Bethesda, MD; MacroGenics, Inc, Rockville, MD; MDR Global Systems, Windber, PA; Medical College of Wisconsin, Milwaukee, WI; Murtha Cancer Center, Uniformed Services University / Walter Reed National Military Medical Center, Bethesda, MD
| | - Y Ru
- Chan Soon-Shiong Institute of Molecular Medicine at Windber, Windber, PA; Clinical Breast Care Project, Murtha Cancer Center, Uniformed Services University / Walter Reed National Military Medical Center, Bethesda, MD; National Institutes of Health, Bethesda, MD; MacroGenics, Inc, Rockville, MD; MDR Global Systems, Windber, PA; Medical College of Wisconsin, Milwaukee, WI; Murtha Cancer Center, Uniformed Services University / Walter Reed National Military Medical Center, Bethesda, MD
| | - AW Kovatich
- Chan Soon-Shiong Institute of Molecular Medicine at Windber, Windber, PA; Clinical Breast Care Project, Murtha Cancer Center, Uniformed Services University / Walter Reed National Military Medical Center, Bethesda, MD; National Institutes of Health, Bethesda, MD; MacroGenics, Inc, Rockville, MD; MDR Global Systems, Windber, PA; Medical College of Wisconsin, Milwaukee, WI; Murtha Cancer Center, Uniformed Services University / Walter Reed National Military Medical Center, Bethesda, MD
| | - B Deyarmin
- Chan Soon-Shiong Institute of Molecular Medicine at Windber, Windber, PA; Clinical Breast Care Project, Murtha Cancer Center, Uniformed Services University / Walter Reed National Military Medical Center, Bethesda, MD; National Institutes of Health, Bethesda, MD; MacroGenics, Inc, Rockville, MD; MDR Global Systems, Windber, PA; Medical College of Wisconsin, Milwaukee, WI; Murtha Cancer Center, Uniformed Services University / Walter Reed National Military Medical Center, Bethesda, MD
| | - JL Fantacone-Campbell
- Chan Soon-Shiong Institute of Molecular Medicine at Windber, Windber, PA; Clinical Breast Care Project, Murtha Cancer Center, Uniformed Services University / Walter Reed National Military Medical Center, Bethesda, MD; National Institutes of Health, Bethesda, MD; MacroGenics, Inc, Rockville, MD; MDR Global Systems, Windber, PA; Medical College of Wisconsin, Milwaukee, WI; Murtha Cancer Center, Uniformed Services University / Walter Reed National Military Medical Center, Bethesda, MD
| | - JA Hooke
- Chan Soon-Shiong Institute of Molecular Medicine at Windber, Windber, PA; Clinical Breast Care Project, Murtha Cancer Center, Uniformed Services University / Walter Reed National Military Medical Center, Bethesda, MD; National Institutes of Health, Bethesda, MD; MacroGenics, Inc, Rockville, MD; MDR Global Systems, Windber, PA; Medical College of Wisconsin, Milwaukee, WI; Murtha Cancer Center, Uniformed Services University / Walter Reed National Military Medical Center, Bethesda, MD
| | - PK Raj Kumar
- Chan Soon-Shiong Institute of Molecular Medicine at Windber, Windber, PA; Clinical Breast Care Project, Murtha Cancer Center, Uniformed Services University / Walter Reed National Military Medical Center, Bethesda, MD; National Institutes of Health, Bethesda, MD; MacroGenics, Inc, Rockville, MD; MDR Global Systems, Windber, PA; Medical College of Wisconsin, Milwaukee, WI; Murtha Cancer Center, Uniformed Services University / Walter Reed National Military Medical Center, Bethesda, MD
| | - H Rui
- Chan Soon-Shiong Institute of Molecular Medicine at Windber, Windber, PA; Clinical Breast Care Project, Murtha Cancer Center, Uniformed Services University / Walter Reed National Military Medical Center, Bethesda, MD; National Institutes of Health, Bethesda, MD; MacroGenics, Inc, Rockville, MD; MDR Global Systems, Windber, PA; Medical College of Wisconsin, Milwaukee, WI; Murtha Cancer Center, Uniformed Services University / Walter Reed National Military Medical Center, Bethesda, MD
| | - H Hu
- Chan Soon-Shiong Institute of Molecular Medicine at Windber, Windber, PA; Clinical Breast Care Project, Murtha Cancer Center, Uniformed Services University / Walter Reed National Military Medical Center, Bethesda, MD; National Institutes of Health, Bethesda, MD; MacroGenics, Inc, Rockville, MD; MDR Global Systems, Windber, PA; Medical College of Wisconsin, Milwaukee, WI; Murtha Cancer Center, Uniformed Services University / Walter Reed National Military Medical Center, Bethesda, MD
| | - CD Shriver
- Chan Soon-Shiong Institute of Molecular Medicine at Windber, Windber, PA; Clinical Breast Care Project, Murtha Cancer Center, Uniformed Services University / Walter Reed National Military Medical Center, Bethesda, MD; National Institutes of Health, Bethesda, MD; MacroGenics, Inc, Rockville, MD; MDR Global Systems, Windber, PA; Medical College of Wisconsin, Milwaukee, WI; Murtha Cancer Center, Uniformed Services University / Walter Reed National Military Medical Center, Bethesda, MD
| |
Collapse
|
11
|
Zhang X, Rui H, Zhang F, Hu Z, Xia Y, Shen Z. Overexpression of a Functional Vicia sativa PCS1 Homolog Increases Cadmium Tolerance and Phytochelatins Synthesis in Arabidopsis. Front Plant Sci 2018; 9:107. [PMID: 29467781 PMCID: PMC5808204 DOI: 10.3389/fpls.2018.00107] [Citation(s) in RCA: 30] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/04/2017] [Accepted: 01/19/2018] [Indexed: 05/05/2023]
Abstract
Phytochelatins (PCs) catalyzed by phytochelatin synthases (PCS) are important for the detoxification of metals in plants and other living organisms. In this study, we isolated a PCS gene (VsPCS1) from Vicia sativa and investigated its role in regulating cadmium (Cd) tolerance. Expression of VsPCS1 was induced in roots of V. sativa under Cd stress. Analysis of subcellular localization showed that VsPCS1 was localized in the cytoplasm of mesophyll protoplasts of V. sativa. Overexpression of VsPCS1 (35S::VsPCS1, in wild-type background) in Arabidopsis thaliana could complement the defects of Cd tolerance of AtPCS1-deficent mutant (atpcs1). Compared with atpcs1 mutants, 35S::VsPCS1/atpcs1 (in AtPCS1-deficent mutant background) transgenic plants significantly lowered Cd-fluorescence intensity in mesophyll cytoplasm, accompanied with enhanced Cd-fluorescence intensity in the vacuoles, demonstrating that the increased Cd tolerance may be attributed to the increased PC-based sequestration of Cd into the vacuole. Furthermore, overexpressing VsPCS1 could enhance the Cd tolerance in 35S::VsPCS1, but have no effect on Cd accumulation and distribution, showing the same level of Cd-fluorescence intensity between 35S::VsPCS1 and wild-type (WT) plants. Further analysis indicated this increased tolerance in 35S::VsPCS1 was possibly due to the increased PCs-chelated Cd in cytosol. Taken together, a functional PCS1 homolog from V. sativa was identified, which hold a strong catalyzed property for the synthesis of high-order PCs that retained Cd in the cytosol rather the vacuole. These findings enrich the original model of Cd detoxification mediated by PCS in higher plants.
Collapse
Affiliation(s)
- Xingxing Zhang
- College of Life Sciences, Nanjing Agricultural University, Nanjing, China
| | - Haiyun Rui
- College of Pharmacy and Chemistry and Chemical Engineering, Taizhou University, Taizhou, China
| | - Fenqin Zhang
- College of Agriculture and Biotechnology, Hexi University, Zhangye, China
| | - Zhubing Hu
- College of Life Sciences, Nanjing Agricultural University, Nanjing, China
| | - Yan Xia
- College of Life Sciences, Nanjing Agricultural University, Nanjing, China
- *Correspondence: Yan Xia,
| | - Zhenguo Shen
- College of Life Sciences, Nanjing Agricultural University, Nanjing, China
| |
Collapse
|
12
|
Gonyo P, Bergom C, Brandt AC, Tsaih SW, Sun Y, Bigley TM, Lorimer EL, Terhune SS, Rui H, Flister MJ, Long RM, Williams CL. SmgGDS is a transient nucleolar protein that protects cells from nucleolar stress and promotes the cell cycle by regulating DREAM complex gene expression. Oncogene 2017; 36:6873-6883. [PMID: 28806394 PMCID: PMC5730474 DOI: 10.1038/onc.2017.280] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2017] [Revised: 06/07/2017] [Accepted: 07/03/2017] [Indexed: 12/19/2022]
Abstract
The chaperone protein and guanine nucleotide exchange factor SmgGDS (RAP1GDS1) is a key promoter of cancer cell proliferation and tumorigenesis. SmgGDS undergoes nucleocytoplasmic shuttling, suggesting that it has both cytoplasmic and nuclear functions that promote cancer. Previous studies indicate that SmgGDS binds cytoplasmic small GTPases and promotes their trafficking to the plasma membrane. In contrast, little is known about the functions of SmgGDS in the nucleus, or how these nuclear functions might benefit cancer cells. Here we show unique nuclear localization and regulation of gene transcription pathways by SmgGDS. Strikingly, SmgGDS depletion significantly reduces expression of over 600 gene products that are targets of the DREAM complex, which is a transcription factor complex that regulates expression of proteins controlling the cell cycle. The cell cycle regulators E2F1, MYC, MYBL2 (B-Myb) and FOXM1 are among the DREAM targets that are diminished by SmgGDS depletion. E2F1 is well known to promote G1 cell cycle progression, and the loss of E2F1 in SmgGDS-depleted cells provides an explanation for previous reports that SmgGDS depletion characteristically causes a G1 cell cycle arrest. We show that SmgGDS localizes in nucleoli, and that RNAi-mediated depletion of SmgGDS in cancer cells disrupts nucleolar morphology, signifying nucleolar stress. We show that nucleolar SmgGDS interacts with the RNA polymerase I transcription factor upstream binding factor (UBF). The RNAi-mediated depletion of UBF diminishes nucleolar localization of SmgGDS and promotes proteasome-mediated degradation of SmgGDS, indicating that nucleolar sequestration of SmgGDS by UBF stabilizes SmgGDS protein. The ability of SmgGDS to interact with UBF and localize in the nucleolus is diminished by expressing DiRas1 or DiRas2, which are small GTPases that bind SmgGDS and act as tumor suppressors. Taken together, our results support a novel nuclear role for SmgGDS in protecting malignant cells from nucleolar stress, thus promoting cell cycle progression and tumorigenesis.
Collapse
Affiliation(s)
- P Gonyo
- Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, WI, USA.,Cancer Center, Medical College of Wisconsin, Milwaukee, WI, USA
| | - C Bergom
- Cancer Center, Medical College of Wisconsin, Milwaukee, WI, USA.,Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, USA
| | - A C Brandt
- Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, WI, USA.,Cancer Center, Medical College of Wisconsin, Milwaukee, WI, USA
| | - S-W Tsaih
- Department of Physiology, Medical College of Wisconsin, Milwaukee, WI, USA
| | - Y Sun
- Department of Pathology, Medical College of Wisconsin, Milwaukee, WI, USA
| | - T M Bigley
- Department of Microbiology and Immunology, Medical College of Wisconsin, Milwaukee, WI, USA.,Department of Pediatrics, Washington University in St Louis, St Louis, MO, USA
| | - E L Lorimer
- Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, WI, USA.,Cancer Center, Medical College of Wisconsin, Milwaukee, WI, USA
| | - S S Terhune
- Department of Microbiology and Immunology, Medical College of Wisconsin, Milwaukee, WI, USA.,Biotechnology and Bioengineering Center, Medical College of Wisconsin, Milwaukee, WI, USA
| | - H Rui
- Cancer Center, Medical College of Wisconsin, Milwaukee, WI, USA.,Department of Pathology, Medical College of Wisconsin, Milwaukee, WI, USA
| | - M J Flister
- Cancer Center, Medical College of Wisconsin, Milwaukee, WI, USA.,Department of Physiology, Medical College of Wisconsin, Milwaukee, WI, USA.,Human and Molecular Genetics Center, Medical College of Wisconsin, Milwaukee, WI, USA.,Cardiovascular Center, Medical College of Wisconsin, Milwaukee, WI, USA
| | - R M Long
- Department of Microbiology and Immunology, Medical College of Wisconsin, Milwaukee, WI, USA.,Medical College of Wisconsin Central Wisconsin Campus, Wausau, WI, USA
| | - C L Williams
- Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, WI, USA.,Cancer Center, Medical College of Wisconsin, Milwaukee, WI, USA.,Cardiovascular Center, Medical College of Wisconsin, Milwaukee, WI, USA
| |
Collapse
|
13
|
Check J, Rosenberg A, Check D, DiAntonio A, Rui H, Cohen R, DiAntonio G. Serum levels of the immunomodulatory protein, the progesterone induced blocking factor (PIBF) which is found in high levels during pregnancy is not higher in women with progesterone (P) receptor (R) positive vs. negative breast cancer. CLIN EXP OBSTET GYN 2017. [DOI: 10.12891/ceog3315.2017] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022]
|
14
|
Check JH, Rosenberg A, Check DL, DiAntonio A, Rui H, Cohen R, DiAntonio G. Serum levels of the immunomodulatory protein, the progesterone induced blocking factor (PIBF) which is found in high levels during pregnancy is not higher in women with progesterone (P) receptor (R) positive vs. negative breast cancer. CLIN EXP OBSTET GYN 2017; 44:187-189. [PMID: 29746019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
PURPOSE To determine if serum levels of the immunomodulatory protein, the progesterone induced blocking factor (PIBF), which is present in high levels during normal pregnancy, is present in higher levels in women with breast cancer positive for progesterone receptors. The study would also determine whether the presence or absence of the estrogen receptor in any way modifies PIBF expression. MATERIALS AND METHODS PIBF using a research ELISA was evaluated in the follicular phase in 21 women with receptor status as follows: seven with estrogen receptor (ER)+ and progesterone receptor (PR)+, seven with ER- and PR+, and seven with ER+ and PR. RESULTS The results showed no differences in serum PIBF in the three groups. The serum PIBF levels were no different than historical controls in the follicular phase. CONCLUSIONS Measurement of serum PIBF does not seem to be an important marker to use to either detect women with breast cancer or to help determine tumor virulence or potential specific therapies. If PIBF plays a role in helping cancer cells to escape immune surveillance, it seems that the intracytoplasmic PIBF would be the form most likely operative.
Collapse
|
15
|
He Y, Rui H, Chen C, Chen Y, Shen Z. The role of roots in the accumulation and removal of cadmium by the aquatic plant Hydrilla verticillata. Environ Sci Pollut Res Int 2016; 23:13308-13316. [PMID: 27023818 DOI: 10.1007/s11356-016-6505-8] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/08/2015] [Accepted: 03/17/2016] [Indexed: 06/05/2023]
Abstract
Aquatic macrophytes can absorb heavy metals either from sediments via the root system, from the water phase by leaves, or from both sources. In this study, cadmium accumulation and distribution in the aquatic plant Hydrilla verticillata were investigated, with a focus on the role of roots. Results showed that leaves of H. verticillata had a higher Cd concentration than roots when intact plants were grown in sediments and solutions containing Cd. Cadmium can significantly decrease the leaf chlorophyll content, and the leaves of intact plants with roots had lower chlorophyll contents than the leaves of detached ones without roots due to the transfer effect of roots. The majority of the Cd accumulated in leaves of H. verticillata was bound to the cell walls. When roots were submerged in a solution containing Cd, with shoots in a control solution without Cd, the Cd concentrations in leaves were considerably lower than in roots. In contrast, Cd was almost undetectable in roots when the shoots were submerged in a solution containing Cd, with roots in the control solution. Compared to the leaves and stems of detached shoots without roots, the concentrations of Cd were much higher in the leaves and stems of intact plants with roots. It is suggested that the roots of intact plants absorb Cd and transfer it to leaves and that more Cd is removed from the solution by intact plants.
Collapse
Affiliation(s)
- Yan He
- College of Life Sciences, Nanjing Agricultural University, Nanjing, 210095, People's Republic of China
| | - Haiyun Rui
- College of Life Sciences, Nanjing Agricultural University, Nanjing, 210095, People's Republic of China
- Taizhou University, Taizhou, 225300, People's Republic of China
| | - Chen Chen
- College of Life Sciences, Nanjing Agricultural University, Nanjing, 210095, People's Republic of China
| | - Yahua Chen
- College of Life Sciences, Nanjing Agricultural University, Nanjing, 210095, People's Republic of China
| | - Zhenguo Shen
- College of Life Sciences, Nanjing Agricultural University, Nanjing, 210095, People's Republic of China.
| |
Collapse
|
16
|
Craig J, Kovatich AJ, Hooke JA, Kvecher L, Liu J, Fantacone-Campbell JL, Rui H, Shriver CD, Hu H. Abstract P4-09-14: PhosphohistoneH3 as a prognostic marker in breast cancer: High expression is associated with younger age, triple negative subtype, and disease specific survival. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p4-09-14] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND PhosphohistoneH3 (PPH3) is an emerging marker in breast cancer and has been linked to both patient survival and age. Phosphorylation of HistoneH3 is an important step during the cell cycle leading to proper compaction of the chromatin during late G2 and early mitosis. Here we assessed the use of PPH3 as a prognostic marker within a group of invasive breast cancers in the Clinical Breast Care Project (CBCP).
METHODS CBCP participants and their samples were collected following IRB-approved, HIPAA-compliant protocols. Samples from 157 CBCP patients were selected for tissue whole section immunohistochemistry (IHC), using antibodies to PPH3, ER, PR, Ki67, and Her2. For each sample, staining of PPH3 was assessed across 5 high powered microscope fields and was considered positive if there was on average >2 stained cells per field. ER and PR were considered positive when there was >5% nuclear staining, and Ki67 was positive when there was >15% nuclear staining. Her2 was considered positive with an IHC score of 3+ or 2+ with a FISH score above 2.2. The samples were subtyped as Luminal A (LA: ER+/HER2-/Ki67-), Luminal B1 (LB1: ER+/HER2-/Ki67+), Luminal B2 (LB2: ER+/HER2+), Her2+ (ER-/PR-/HER2+), and Triple Negative (TN: ER-/PR-/HER2-). PPH3 was tested for associations with age and subtype using a stratified univariate Wilcoxon rank-sum analysis and a multivariate analysis controlling for subtype. To test the efficacy of PPH3 as a prognostic marker, Kaplan-Meier curves for disease specific survival were analyzed and the cox proportional hazard regression model was calculated. Further analysis addressing population demographics and additional cancer characteristics is ongoing.
RESULTS Wilcoxon analysis revealed an association between higher PPH3 levels and younger age (P=.0038). Subtype was also found to be associated with PPH3, with the TN subtype 6.26 times more likely to have higher PPH3 expression than LA (P=.005). The association with age was confirmed by repeating the analysis and stratifying into non-TN subtypes (P=.05) and TN only subtype (P=.017). Non-TN subtypes positive for PPH3 expression had median age of 53.18 at diagnosis and 63.29 for negative PPH3 expression; TN subtypes that were positive for PPH3 had a median age of 50.44 and 72.9 for negative PPH3. Multivariate analysis with age and subtype as the variables also supported these results (age P=.017; TN vs LA P=.022). Disease specific survival analysis showed that a shorter survival time was associated with positive PPH3 protein levels (P=0.03; hazard ratio=6.97).
CONCLUSIONS High expression of PPH3 is associated with a younger age, poorer survival rate, and the TN subtype. These results corroborate the use of PPH3 as a prognostic marker for breast cancer patients.
The views expressed in this article are those of the author and do not reflect the official policy of the Department of Defense, or U.S. Government.
Citation Format: Craig J, Kovatich AJ, Hooke JA, Kvecher L, Liu J, Fantacone-Campbell JL, Rui H, Shriver CD, Hu H. PhosphohistoneH3 as a prognostic marker in breast cancer: High expression is associated with younger age, triple negative subtype, and disease specific survival. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P4-09-14.
Collapse
Affiliation(s)
- J Craig
- Windber Research Institute, Windber, PA; Clinical Breast Care Project, Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD; Thomas Jefferson University, Philadelphia, PA; Walter Reed National Military Medical Center, Bethesda, MD
| | - AJ Kovatich
- Windber Research Institute, Windber, PA; Clinical Breast Care Project, Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD; Thomas Jefferson University, Philadelphia, PA; Walter Reed National Military Medical Center, Bethesda, MD
| | - JA Hooke
- Windber Research Institute, Windber, PA; Clinical Breast Care Project, Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD; Thomas Jefferson University, Philadelphia, PA; Walter Reed National Military Medical Center, Bethesda, MD
| | - L Kvecher
- Windber Research Institute, Windber, PA; Clinical Breast Care Project, Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD; Thomas Jefferson University, Philadelphia, PA; Walter Reed National Military Medical Center, Bethesda, MD
| | - J Liu
- Windber Research Institute, Windber, PA; Clinical Breast Care Project, Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD; Thomas Jefferson University, Philadelphia, PA; Walter Reed National Military Medical Center, Bethesda, MD
| | - JL Fantacone-Campbell
- Windber Research Institute, Windber, PA; Clinical Breast Care Project, Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD; Thomas Jefferson University, Philadelphia, PA; Walter Reed National Military Medical Center, Bethesda, MD
| | - H Rui
- Windber Research Institute, Windber, PA; Clinical Breast Care Project, Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD; Thomas Jefferson University, Philadelphia, PA; Walter Reed National Military Medical Center, Bethesda, MD
| | - CD Shriver
- Windber Research Institute, Windber, PA; Clinical Breast Care Project, Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD; Thomas Jefferson University, Philadelphia, PA; Walter Reed National Military Medical Center, Bethesda, MD
| | - H Hu
- Windber Research Institute, Windber, PA; Clinical Breast Care Project, Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD; Thomas Jefferson University, Philadelphia, PA; Walter Reed National Military Medical Center, Bethesda, MD
| |
Collapse
|
17
|
Oesterreich S, Katz TA, Logan G, Levine K, Nagle A, Huo Z, Tseng GC, Rui H, Lee AV, Butler LM. Abstract PD2-08: Potential role of prolactin signaling in development and growth of the lobular subtype of breast cancer. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-pd2-08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Invasive lobular carcinoma (ILC) is the eighth most frequently diagnosed cancer in any organ, and accounts for 8-11% of breast cancer. This histological subtype is characterized by loss of E-cadherin, and favorable prognostic factors, such as low Ki67 and high rates of ER/PR-positive tumors. Only recently is the lobular subtype gaining recognition as a distinct disease, displaying a unique growth pattern, unique molecular changes in addition to loss of E-cadherin, and evidence for late recurrences and reduced response to targeted endocrine therapy. It is widely accepted that a late age at first full term birth (FFTB) increases a women's risk for breast cancer. Interestingly, several published epidemiological studies have shown that the increased risk after a late age at FFTB is preferential for the lobular subtype of breast cancer compared to the ductal subtype. We therefore hypothesized that pregnancy hormones like prolactin play an integral role in the development and progression of ILC. Interrogation of the Cancer Genome Atlas (TCGA) data revealed a high expression of milk protein genes as well as prolactin signaling molecules, specifically Stat5a and Stat5b in lobular carcinomas compared to ductal carcinomas. We developed a lactation score including 7 milk protein genes and found that in the TCGA data set ILC tumors have a significantly higher lactation score than IDC tumors. Additionally, we found that ILC cell lines express increased prolactin receptor mRNA and protein levels compared to IDC cell lines. Prolactin treatment in ILC and IDC cells reveals divergent signaling pathways - prolactin stimulates ERK activation in IDC but not ILC cells. We are currently further delineating the prolactin signaling pathways, and resulting phenotypes, comparing ILC and IDC cells. We expect these experiments to move the field forward by establishing a relationship between prolactin and lobular carcinoma.
Citation Format: Oesterreich S, Katz TA, Logan G, Levine K, Nagle A, Huo Z, Tseng GC, Rui H, Lee AV, Butler LM. Potential role of prolactin signaling in development and growth of the lobular subtype of breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr PD2-08.
Collapse
Affiliation(s)
- S Oesterreich
- Univeristy of Pittsburgh Cancer Institute, Pittburgh, PA; University of Pittsburgh, Pittsburgh, PA; Univesity of Pittsburgh, Pittsburgh, PA; Kimmel Cancer Center, Philadelphia, PA
| | - TA Katz
- Univeristy of Pittsburgh Cancer Institute, Pittburgh, PA; University of Pittsburgh, Pittsburgh, PA; Univesity of Pittsburgh, Pittsburgh, PA; Kimmel Cancer Center, Philadelphia, PA
| | - G Logan
- Univeristy of Pittsburgh Cancer Institute, Pittburgh, PA; University of Pittsburgh, Pittsburgh, PA; Univesity of Pittsburgh, Pittsburgh, PA; Kimmel Cancer Center, Philadelphia, PA
| | - K Levine
- Univeristy of Pittsburgh Cancer Institute, Pittburgh, PA; University of Pittsburgh, Pittsburgh, PA; Univesity of Pittsburgh, Pittsburgh, PA; Kimmel Cancer Center, Philadelphia, PA
| | - A Nagle
- Univeristy of Pittsburgh Cancer Institute, Pittburgh, PA; University of Pittsburgh, Pittsburgh, PA; Univesity of Pittsburgh, Pittsburgh, PA; Kimmel Cancer Center, Philadelphia, PA
| | - Z Huo
- Univeristy of Pittsburgh Cancer Institute, Pittburgh, PA; University of Pittsburgh, Pittsburgh, PA; Univesity of Pittsburgh, Pittsburgh, PA; Kimmel Cancer Center, Philadelphia, PA
| | - GC Tseng
- Univeristy of Pittsburgh Cancer Institute, Pittburgh, PA; University of Pittsburgh, Pittsburgh, PA; Univesity of Pittsburgh, Pittsburgh, PA; Kimmel Cancer Center, Philadelphia, PA
| | - H Rui
- Univeristy of Pittsburgh Cancer Institute, Pittburgh, PA; University of Pittsburgh, Pittsburgh, PA; Univesity of Pittsburgh, Pittsburgh, PA; Kimmel Cancer Center, Philadelphia, PA
| | - AV Lee
- Univeristy of Pittsburgh Cancer Institute, Pittburgh, PA; University of Pittsburgh, Pittsburgh, PA; Univesity of Pittsburgh, Pittsburgh, PA; Kimmel Cancer Center, Philadelphia, PA
| | - LM Butler
- Univeristy of Pittsburgh Cancer Institute, Pittburgh, PA; University of Pittsburgh, Pittsburgh, PA; Univesity of Pittsburgh, Pittsburgh, PA; Kimmel Cancer Center, Philadelphia, PA
| |
Collapse
|
18
|
Rui H, Chen C, Zhang X, Shen Z, Zhang F. Cd-induced oxidative stress and lignification in the roots of two Vicia sativa L. varieties with different Cd tolerances. J Hazard Mater 2016; 301:304-13. [PMID: 26372696 DOI: 10.1016/j.jhazmat.2015.08.052] [Citation(s) in RCA: 68] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/13/2015] [Revised: 08/25/2015] [Accepted: 08/27/2015] [Indexed: 05/22/2023]
Abstract
We examined the effects of Cd on growth, lipid peroxidation, reactive oxygen species (ROS) accumulation, antioxidant enzymatic activity, and lignin content in the roots of two varieties of Vicia sativa. Treatment with Cd decreased plant growth and increased ROS and lipid peroxidation levels to a greater extent in the Cd-sensitive variety ZM than in the Cd-tolerant variety L3. Most hydrogen peroxide (H2O2) and superoxide anion (O2(•-)) were accumulated in the cell walls and extracellular spaces in response to Cd treatments. Chemical assays and experiments using inhibitors showed that larger increases in H2O2 and O2(•-) production in ZM than in L3 were probably attributed to elevated Cd-induced nicotinamide adenine dinucleotide-peroxidase (NADH-POD) activity. Cd treatment increased the accumulation of lignin and the guaiacol peroxidase (GPOD) activities in the apoplast more significantly in ZM root than in L3. Howerver, root laccase activity was higher in L3 than in ZM. Thus Cd toxicity induced significant lignification in the roots of V. sativa, and increases in H2O2 accumulation and apoplastic GPOD activity were likely responsible for this effect.
Collapse
Affiliation(s)
- Haiyun Rui
- College of Life Sciences, Nanjing Agricultural University, Nanjing 210095, People's Republic of China; Taizhou University, Taizhou 225300, People's Republic of China
| | - Chen Chen
- College of Life Sciences, Nanjing Agricultural University, Nanjing 210095, People's Republic of China
| | - Xingxing Zhang
- College of Life Sciences, Nanjing Agricultural University, Nanjing 210095, People's Republic of China
| | - Zhenguo Shen
- College of Life Sciences, Nanjing Agricultural University, Nanjing 210095, People's Republic of China.
| | - Fenqin Zhang
- College of Agriculture and Biotechnology, Hexi University, Zhangye 734000, People's Republic of China.
| |
Collapse
|
19
|
Blanco FF, Jimbo M, Wulfkuhle J, Gallagher I, Deng J, Enyenihi L, Meisner-Kober N, Londin E, Rigoutsos I, Sawicki JA, Risbud MV, Witkiewicz AK, McCue PA, Jiang W, Rui H, Yeo CJ, Petricoin E, Winter JM, Brody JR. The mRNA-binding protein HuR promotes hypoxia-induced chemoresistance through posttranscriptional regulation of the proto-oncogene PIM1 in pancreatic cancer cells. Oncogene 2015; 35:2529-41. [PMID: 26387536 DOI: 10.1038/onc.2015.325] [Citation(s) in RCA: 76] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2015] [Revised: 07/08/2015] [Accepted: 07/10/2015] [Indexed: 12/15/2022]
Abstract
Previously, it has been shown that pancreatic ductal adenocarcinoma (PDA) tumors exhibit high levels of hypoxia, characterized by low oxygen pressure (pO2) and decreased O2 intracellular perfusion. Chronic hypoxia is strongly associated with resistance to cytotoxic chemotherapy and chemoradiation in an understudied phenomenon known as hypoxia-induced chemoresistance. The hypoxia-inducible, pro-oncogenic, serine-threonine kinase PIM1 (Proviral Integration site for Moloney murine leukemia virus 1) has emerged as a key regulator of hypoxia-induced chemoresistance in PDA and other cancers. Although its role in therapeutic resistance has been described previously, the molecular mechanism behind PIM1 overexpression in PDA is unknown. Here, we demonstrate that cis-acting AU-rich elements (ARE) present within a 38-base pair region of the PIM1 mRNA 3'-untranslated region mediate a regulatory interaction with the mRNA stability factor HuR (Hu antigen R) in the context of tumor hypoxia. Predominantly expressed in the nucleus in PDA cells, HuR translocates to the cytoplasm in response to hypoxic stress and stabilizes the PIM1 mRNA transcript, resulting in PIM1 protein overexpression. A reverse-phase protein array revealed that HuR-mediated regulation of PIM1 protects cells from hypoxic stress through phosphorylation and inactivation of the apoptotic effector BAD and activation of MEK1/2. Importantly, pharmacological inhibition of HuR by MS-444 inhibits HuR homodimerization and its cytoplasmic translocation, abrogates hypoxia-induced PIM1 overexpression and markedly enhances PDA cell sensitivity to oxaliplatin and 5-fluorouracil under physiologic low oxygen conditions. Taken together, these results support the notion that HuR has prosurvival properties in PDA cells by enabling them with growth advantages in stressful tumor microenvironment niches. Accordingly, these studies provide evidence that therapeutic disruption of HuR's regulation of PIM1 may be a key strategy in breaking an elusive chemotherapeutic resistance mechanism acquired by PDA cells that reside in hypoxic PDA microenvironments.
Collapse
Affiliation(s)
- F F Blanco
- Department of Pharmacology and Experimental Therapeutics, Division of Clinical Pharmacology, Thomas Jefferson University, Philadelphia, PA, USA.,Department of Surgery, Thomas Jefferson University, Philadelphia, PA, USA
| | - M Jimbo
- Department of Surgery, Thomas Jefferson University, Philadelphia, PA, USA
| | - J Wulfkuhle
- Center for Applied Proteomics and Molecular Medicine, School of Systems Biology, George Mason University, Manassas, VA, USA
| | - I Gallagher
- Center for Applied Proteomics and Molecular Medicine, School of Systems Biology, George Mason University, Manassas, VA, USA
| | - J Deng
- Center for Applied Proteomics and Molecular Medicine, School of Systems Biology, George Mason University, Manassas, VA, USA
| | - L Enyenihi
- Department of Surgery, Thomas Jefferson University, Philadelphia, PA, USA
| | - N Meisner-Kober
- Novartis Institutes for Biomedical Research, Novartis, Switzerland
| | - E Londin
- Center for Computational Medicine, Thomas Jefferson University, Philadelphia, PA, USA
| | - I Rigoutsos
- Center for Computational Medicine, Thomas Jefferson University, Philadelphia, PA, USA
| | - J A Sawicki
- Lankenau Institute for Medical Research, Philadelphia, PA, USA
| | - M V Risbud
- Department of Orthopedic Surgery, Thomas Jefferson University, Philadelphia, PA, USA
| | - A K Witkiewicz
- Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA
| | - P A McCue
- Department of Pathology, Thomas Jefferson University, Philadelphia, PA, USA
| | - W Jiang
- Department of Pathology, Thomas Jefferson University, Philadelphia, PA, USA
| | - H Rui
- Department of Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA
| | - C J Yeo
- Department of Surgery, Thomas Jefferson University, Philadelphia, PA, USA
| | - E Petricoin
- Center for Applied Proteomics and Molecular Medicine, School of Systems Biology, George Mason University, Manassas, VA, USA
| | - J M Winter
- Department of Surgery, Thomas Jefferson University, Philadelphia, PA, USA
| | - J R Brody
- Department of Surgery, Thomas Jefferson University, Philadelphia, PA, USA
| |
Collapse
|
20
|
Goodman CR, Sato T, Peck AR, Girondo MA, Yang N, Liu C, Yanac AF, Kovatich AJ, Hooke JA, Shriver CD, Mitchell EP, Hyslop T, Rui H. Steroid induction of therapy-resistant cytokeratin-5-positive cells in estrogen receptor-positive breast cancer through a BCL6-dependent mechanism. Oncogene 2015; 35:1373-85. [PMID: 26096934 PMCID: PMC4800289 DOI: 10.1038/onc.2015.193] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2015] [Revised: 04/08/2015] [Accepted: 05/04/2015] [Indexed: 12/11/2022]
Abstract
Therapy resistance remains a major problem in estrogen receptor-α (ERα)-positive breast cancer. A subgroup of ERα-positive breast cancer is characterized by mosaic presence of a minor population of ERα-negative cancer cells expressing the basal cytokeratin-5 (CK5). These CK5-positive cells are therapy resistant and have increased tumor-initiating potential. Although a series of reports document induction of the CK5-positive cells by progestins, it is unknown if other 3-ketosteroids share this ability. We now report that glucocorticoids and mineralocorticoids effectively expand the CK5-positive cell population. CK5-positive cells induced by 3-ketosteroids lacked ERα and progesterone receptors, expressed stem cell marker, CD44, and displayed increased clonogenicity in soft agar and broad drug-resistance in vitro and in vivo. Upregulation of CK5-positive cells by 3-ketosteroids required induction of the transcriptional repressor BCL6 based on suppression of BCL6 by two independent BCL6 small hairpin RNAs or by prolactin. Prolactin also suppressed 3-ketosteroid induction of CK5+ cells in T47D xenografts in vivo. Survival analysis with recursive partitioning in node-negative ERα-positive breast cancer using quantitative CK5 and BCL6 mRNA or protein expression data identified patients at high or low risk for tumor recurrence in two independent patient cohorts. The data provide a mechanism by which common pathophysiological or pharmacologic elevations in glucocorticoids or other 3-ketosteroids may adversely affect patients with mixed ERα+/CK5+ breast cancer. The observations further suggest a cooperative diagnostic utility of CK5 and BCL6 expression levels and justify exploring efficacy of inhibitors of BCL6 and 3-ketosteroid receptors for a subset of ERα-positive breast cancers.
Collapse
Affiliation(s)
- C R Goodman
- Department of Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA
| | - T Sato
- Department of Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA
| | - A R Peck
- Department of Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA
| | - M A Girondo
- Department of Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA
| | - N Yang
- Department of Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA
| | - C Liu
- Department of Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA
| | - A F Yanac
- Department of Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA
| | - A J Kovatich
- John P. Murtha Cancer Center, Walter Reed National Military Medical Center, Bethesda, MD, USA
| | - J A Hooke
- John P. Murtha Cancer Center, Walter Reed National Military Medical Center, Bethesda, MD, USA
| | - C D Shriver
- John P. Murtha Cancer Center, Walter Reed National Military Medical Center, Bethesda, MD, USA
| | - E P Mitchell
- Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA, USA
| | - T Hyslop
- Department of Biostatistics & Bioinformatics, Duke Cancer Institute, Duke University, Durham, NC, USA
| | - H Rui
- Department of Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA.,Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA, USA.,Department of Pathology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA
| |
Collapse
|
21
|
Rui H, Zhang J, Yanac AF, Utama FE, Girondo MA, Peck AR, Rosenberg AL, Yang N. Abstract P5-04-05: Preclinical modeling of luminal breast cancer: Recapitulating progression to lethal and tamoxifen-resistant lung metastases in novel patient-derived xenotransplant models in prolactin-humanized mice. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p5-04-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Seventy to eighty percent of newly diagnosed breast cancer cases are estrogen receptor(ER)-positive and are classified as luminal. Despite hormone therapy, 25-30% of luminal breast cancers will recur within 15 years of surgical removal of the primary tumor, and many of these patients will die from currently incurable distant metastases. Lung and bone are the most common organ sites for distant breast cancer metastases, with either site affected in approximately 70% of patients based on autopsy studies. A major hurdle for therapeutic progress with luminal breast cancer is the historical difficulty to establish xenograft models of human luminal breast cancer in mice. In particular, there is a need for experimental ER-positive breast cancer models that recapitulate distant metastasis formation from orthotopic tumor implants in mammary glands. Such experimental models will allow surgical resection of the primary tumor followed by clinically relevant testing of targeted adjuvant agents against distant residual disease.
We have engineered prolactin-humanized mice that have been backcrossed for ten generations into the Nod-SCOD-IL2Rgamma (NSG) immunodeficient background. These prolactin-humanized mice display improved take rates of patient-derived luminal breast cancer. Using prolactin-humanized mice we have established patient-derived serially transplantable luminal breast cancer models that metastasize to distant sites when grown as primary tumors in the mammary gland. One of the ER-positive lines, PDX2, effectively metastasizes to lungs in 100% of animals within 55 days of grafting into mammary glands. PDX2 lung metastases retain ER and progesterone receptor (PR) expression as well as expression of the luminal marker, GATA3, and display high degree of Ki67 positivity indicating rapidly proliferative lesions. Importantly, metastatic PDX2 lesions show only limited dormancy. In fact, when primary PDX2 tumors are surgically removed at Day 55, mice will die from lung metastases around Day 150. Estrogen supplementation is required for establishment of PDX2 tumors in mice. After primary PDX2 tumors are established in mammary glands in the presence of estradiol, primary tumors respond to tamoxifen with growth suppression but do not undergo tumor regression, and develop resistance to tamoxifen. Treatment of mice with adjuvant tamoxifen following surgical removal of primary PDX2 tumors led to extensive regression of existing lung metastases to barely detectable levels within 30 days of surgery. However, tamoxifen-refractory PDX2 lung metastases regrew during the next 30 day-period in the continued exposure to tamoxifen. Molecular phenotyping of the PDX2 model and other new luminal breast cancer models are ongoing, with the goal of characterizing tamoxifen-responsive and tamoxifen-refractory primary and metastatic lesions. Long-term, our intent is to use the PDX2 and other preclinical xenograft models in prolactin-humanized mice to systematically explore agents for synergy with anti-estrogens to establish curative combination treatments for metastatic luminal breast cancer.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P5-04-05.
Collapse
Affiliation(s)
- H Rui
- Thomas Jefferson University, Philadelphia, PA
| | - J Zhang
- Thomas Jefferson University, Philadelphia, PA
| | - AF Yanac
- Thomas Jefferson University, Philadelphia, PA
| | - FE Utama
- Thomas Jefferson University, Philadelphia, PA
| | - MA Girondo
- Thomas Jefferson University, Philadelphia, PA
| | - AR Peck
- Thomas Jefferson University, Philadelphia, PA
| | | | - N Yang
- Thomas Jefferson University, Philadelphia, PA
| |
Collapse
|
22
|
Kovatich AJ, Chen Y, Fantacone-Campbell JL, Wareham JA, Tafra L, Kvecher L, Hyslop T, Hooke JA, Rui H, Shriver CD, Mural RJ, Hu H. Abstract P4-06-03: Assays on core biopsies and surgically resected tumors may result in different subtyping of the invasive breast cancer from the same patient. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p4-06-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background Core biopsies (CBs) are often used for biomarker expression assays to determine the treatment regimen. However, a number of other clinically important analyses (e.g. OncoType Dx), are performed on surgically resected tumors (SRTs). A previous study has shown that biomarkers ER, PR, and Ki67 expressed higher in CBs than in SRTs. Here we analyze how this difference impacts the subtyping of ER+ breast tumors.
Methods Female patients enrolled in the Clinical Breast Care Project (CBCP) from a civilian site were selected for this study, where expression of ER, PR, HER2, and Ki67 were assayed by IHC in a reference lab on CBs; the same 4 assays were performed on SRTs by a CBCP central lab. Both labs are CLIA-certified. Patients treated with neoadjuvant chemotherapy and those with multiple tumors were excluded. 167 cases were identified for this study to compare assays performed on CBs and SRTs from the same patients. ER and PR were positive if >1% nuclear staining, HER2 was negative if IHC = 0 or 1+, positive if IHC = 3+, and for IHC = 2+ FISH was used for the final call. Ki67 was positive if > = 15% nuclear staining. LA was ER+/HER2-/Ki67-, LB1 was ER+/HER2-/Ki67+, and LB2 was ER+/HER2+. For histologic grades, only readings from the central lab on SRTs were used. Statistical analyses were performed using SAS.
Results This analysis confirmed that Ki67, ER, and PR showed higher percent nuclear staining in CBs than in SRTs from the same patients. The difference for Ki67 was more striking and unidirectional. ER and PR cases clustered at the upper percent levels. Histograms with a bin-width of 15% show a peak at 15% for Ki67 difference between CBs and SRTs, whereas the peaks for ER and PR differences were at 0%. McNemar's (or Exact McNemar’s) test showed significant differences between the binary status calls for Ki67 (p = 3.2E-15) and ER (p = 0.012), but not for PR (p = 0.65). Assays on CBs and SRTs resulted in different subtype calls for the cases (Table 1). Grade distributions were different between LA and LB (p<0.001 for both CB- and SRT-based subtypes, Chi-Square or Fisher's Exact test), but not so between LB1 and LB2 (p = 0.23 for CB, 0.31 for SRT). However, SRT-based LB1 cases concentrate more on higher grades compared to CB-based cases (p = 0.048).
Table 1. ER+ subtypes based on IHC assays (from CBs and SRTs) and corresponding grades (from SRTs) CBSRTSubtypeG1G2G3G1G2G3LA2126034518LB11435342820LB2036032
Discussion On IHC assays, Ki67 expression is strikingly higher in CBs than in SRTs, and ER expression is also higher in CBs than in SRTs. This directly resulted in more LB than LA subtypes based on CBs. SRT-based LB1 cases concentrate more on higher grades compared to CB-based cases, which is more consistent with the observation that LB subtypes have worse outcomes. A limitation of this study is that technical differences between the labs may contribute to the observed differences between CBs and SRTs. Further studies need to be performed to determine whether SRT should also be assayed in addition to CB for treatment regimen decision-making.
The views expressed in this abstract are those of the authors and do not reflect the official policy of the Department of Defense, or US Government.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P4-06-03.
Collapse
Affiliation(s)
- AJ Kovatich
- Clinical Breast Care Project, Walter Reed National Military Medical Center, Bethesda, MD; Biomedical Informatics, Windber Research Institute, Windber, PA; Breast Center, Anne Arundel Medical Center, Annapolis, MD; Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA
| | - Y Chen
- Clinical Breast Care Project, Walter Reed National Military Medical Center, Bethesda, MD; Biomedical Informatics, Windber Research Institute, Windber, PA; Breast Center, Anne Arundel Medical Center, Annapolis, MD; Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA
| | - JL Fantacone-Campbell
- Clinical Breast Care Project, Walter Reed National Military Medical Center, Bethesda, MD; Biomedical Informatics, Windber Research Institute, Windber, PA; Breast Center, Anne Arundel Medical Center, Annapolis, MD; Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA
| | - JA Wareham
- Clinical Breast Care Project, Walter Reed National Military Medical Center, Bethesda, MD; Biomedical Informatics, Windber Research Institute, Windber, PA; Breast Center, Anne Arundel Medical Center, Annapolis, MD; Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA
| | - L Tafra
- Clinical Breast Care Project, Walter Reed National Military Medical Center, Bethesda, MD; Biomedical Informatics, Windber Research Institute, Windber, PA; Breast Center, Anne Arundel Medical Center, Annapolis, MD; Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA
| | - L Kvecher
- Clinical Breast Care Project, Walter Reed National Military Medical Center, Bethesda, MD; Biomedical Informatics, Windber Research Institute, Windber, PA; Breast Center, Anne Arundel Medical Center, Annapolis, MD; Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA
| | - T Hyslop
- Clinical Breast Care Project, Walter Reed National Military Medical Center, Bethesda, MD; Biomedical Informatics, Windber Research Institute, Windber, PA; Breast Center, Anne Arundel Medical Center, Annapolis, MD; Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA
| | - JA Hooke
- Clinical Breast Care Project, Walter Reed National Military Medical Center, Bethesda, MD; Biomedical Informatics, Windber Research Institute, Windber, PA; Breast Center, Anne Arundel Medical Center, Annapolis, MD; Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA
| | - H Rui
- Clinical Breast Care Project, Walter Reed National Military Medical Center, Bethesda, MD; Biomedical Informatics, Windber Research Institute, Windber, PA; Breast Center, Anne Arundel Medical Center, Annapolis, MD; Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA
| | - CD Shriver
- Clinical Breast Care Project, Walter Reed National Military Medical Center, Bethesda, MD; Biomedical Informatics, Windber Research Institute, Windber, PA; Breast Center, Anne Arundel Medical Center, Annapolis, MD; Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA
| | - RJ Mural
- Clinical Breast Care Project, Walter Reed National Military Medical Center, Bethesda, MD; Biomedical Informatics, Windber Research Institute, Windber, PA; Breast Center, Anne Arundel Medical Center, Annapolis, MD; Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA
| | - H Hu
- Clinical Breast Care Project, Walter Reed National Military Medical Center, Bethesda, MD; Biomedical Informatics, Windber Research Institute, Windber, PA; Breast Center, Anne Arundel Medical Center, Annapolis, MD; Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA
| |
Collapse
|
23
|
Peck AR, Yang N, Yanac AF, Utama FE, Jasinski JH, Rosenberg AL, Tanaka T, Rui H. Abstract P1-06-10: Characterization of novel activated human mammary fibroblast lines and their protumorigenic effect on human breast cancer xenotransplants in mice. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p1-06-10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Human breast cancer is typically characterized by an extensive stromal compartment enriched in fibroblasts. In contrast, xenotransplants of human breast cancer cell lines are typically epithelial-rich and characterized by sparse in-growth of murine fibroblast stroma. Stromal fibroblasts are important for structural integrity of normal tissue and constitute a major element of the stromal microenvironment of invasive cancer. Cancer associated fibroblasts (CAFs) frequently undergo activation as they co-evolve with cancer cells, serving to promote tumor growth and angiogenesis through secretion of multiple paracrine factors. Presence of activated CAFs in solid malignancies is generally associated with higher grade tumors and poor prognosis. Activated CAFs are resistant to apoptosis and display a myofibroblastic phenotype, including expression of a-smooth muscle actin (α-SMA). To more accurately model human tumor-stroma interactions in human breast cancer xenograft lines in mice, we aimed to develop immortalized activated human mammary fibroblasts for admixture xenografting with human breast cancer cells. Human mammary fibroblasts (HMFs) were isolated from multiple surgically excised tissues of reduction mammoplasties or mastectomies. Five isolated primary HMF lines were screened for α-SMA expression. HMF1 expressed the highest levels of α-SMA and was immortalized by stable lentiviral-delivered hTERT. Quantitative real-time PCR, anchorage-independent growth assay, and in vivo studies were used to further characterize selected HMFs. hTERT-HMF1 and HMF2, despite lower level of α-SMA expression in HMF2, displayed significantly elevated levels of mRNA of proteins commonly associated with activated fibroblasts, including SDF-α, SDF-β, HGF, IL-6, VEGF and podoplanin, as well as promoted a 10-fold increase in anchorage-independent growth of MCF7 breast cancer cells in vitro. To evaluate the ability of these HMF lines to promote tumor growth in vivo, MCF7 human breast cancer cells were orthotopically injected into murine mammary fat pads in the presence or absence of hTERT-HMF1 or HMF2. Both HMF lines facilitated in vivo MCF7-xenograft growth and induced histological changes, including higher grade and greater stromal development, when compared to pure MCF7 cell xenografts. IHC for SMA and collagen confirmed the presence of activated fibroblasts in all tumors; however HMF/MCF7 xenografts showed a distinct distribution of fibroblast stroma throughout the tumor in contrast to sparser stroma between larger epithelial aggregates in tumors grafted from MCF7 cells alone. hTERT-HFM1 cells promoted tumor growth in vivo more robustly than HFM2 cells. By 60 days post xenografting, hTERT-HMF1/MCF7 tumors were significantly larger (∼4-fold) than control MCF7 tumors. In addition, admixture with hTERT-HMF1 cells promoted increased tumor angiogenesis and cancer cell proliferation as measured by Ki67 expression. hTERT-HMF1 represents a novel mammary myofibroblast line that may be useful for improved preclinical xenotransplant modeling and tumor drug response testing of human breast cancer in vivo.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P1-06-10.
Collapse
Affiliation(s)
- AR Peck
- Thomas Jefferson University, Philadelphia, PA
| | - N Yang
- Thomas Jefferson University, Philadelphia, PA
| | - AF Yanac
- Thomas Jefferson University, Philadelphia, PA
| | - FE Utama
- Thomas Jefferson University, Philadelphia, PA
| | - JH Jasinski
- Thomas Jefferson University, Philadelphia, PA
| | | | - T Tanaka
- Thomas Jefferson University, Philadelphia, PA
| | - H Rui
- Thomas Jefferson University, Philadelphia, PA
| |
Collapse
|
24
|
Pestell RG, Chen K, Wu K, Gormley M, Ertel A, Zhang W, Zhou J, DiSante G, Li Z, Rui H, Quong AA, McMahon SB, Deng H, Lisanti MP, Wang C. Abstract P5-11-04: Post-translational modification of the cell-fate factor Dachshund determines p53 binding and signaling modules in breast cancer. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p5-11-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Breast cancer is a leading form of cancer in the world. Initially cloned as a dominant inhibitor of the hyperactive EGFR, Ellipse, in Drosophila, the mammalian DACH1 regulates expression of target genes in part through interacting with DNA-binding transcription factors (c-Jun, Smads, Six, ERα), and in part through intrinsic DNA-sequence specific binding to Forkhead binding sites. The Drosophila dac gene is a key member of the retinal determination gene network (RDGN), which also includes eyes absent (eya), ey, twin of eyeless (toy), teashirt (tsh) and sin oculis (so), that specifies eye tissue identity.
Several lines of evidence suggest DACH1 may function as a tumor suppressor. Clinical studies have demonstrated a correlation between poor prognosis and reduced expression of the cell-fate determination factor DACH1 in breast cancer, and loss of DACH1 expression has been observed in prostate and endometrial cancer. DACH1 inhibits breast cancer tumor metastasis and reduces breast cancer stem cell expansion via Sox2/Nanog. Although these studies suggest DACH1 may function as a tumor suppressor, the molecular mechanisms remain poorly defined. Herein, endogenous DACH1 co-localized with p53 in a nuclear, extranucleolar compartment and bound to p53 in human breast cancer cell lines, p53 and DACH1 bound common genes in ChIP-Seq. Full inhibition of breast cancer contact-independent growth by DACH1 required p53. The p53 breast cancer mutants R248Q and R273H, evaded DACH1 binding. DACH1 phosphorylation at serine residue (S439) inhibited p53 binding and phosphorylation at p53 amino-terminal sites (S15, S20) enhanced DACH1 binding. DACH1 binding to p53 was inhibited by NAD-dependent deacetylation via DACH1 K628. DACH1 repressed p21CIP1 and induced RAD51, an association found in basal breast cancer. DACH1 inhibits breast cancer cellular growth in an NAD and p53 dependent manner through direct protein-protein association.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P5-11-04.
Collapse
Affiliation(s)
- RG Pestell
- Thomas Jefferson University, Philadelphia, PA; Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; Proteomics Resource Center, Rockefeller University, New York, NY
| | - K Chen
- Thomas Jefferson University, Philadelphia, PA; Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; Proteomics Resource Center, Rockefeller University, New York, NY
| | - K Wu
- Thomas Jefferson University, Philadelphia, PA; Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; Proteomics Resource Center, Rockefeller University, New York, NY
| | - M Gormley
- Thomas Jefferson University, Philadelphia, PA; Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; Proteomics Resource Center, Rockefeller University, New York, NY
| | - A Ertel
- Thomas Jefferson University, Philadelphia, PA; Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; Proteomics Resource Center, Rockefeller University, New York, NY
| | - W Zhang
- Thomas Jefferson University, Philadelphia, PA; Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; Proteomics Resource Center, Rockefeller University, New York, NY
| | - J Zhou
- Thomas Jefferson University, Philadelphia, PA; Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; Proteomics Resource Center, Rockefeller University, New York, NY
| | - G DiSante
- Thomas Jefferson University, Philadelphia, PA; Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; Proteomics Resource Center, Rockefeller University, New York, NY
| | - Z Li
- Thomas Jefferson University, Philadelphia, PA; Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; Proteomics Resource Center, Rockefeller University, New York, NY
| | - H Rui
- Thomas Jefferson University, Philadelphia, PA; Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; Proteomics Resource Center, Rockefeller University, New York, NY
| | - AA Quong
- Thomas Jefferson University, Philadelphia, PA; Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; Proteomics Resource Center, Rockefeller University, New York, NY
| | - SB McMahon
- Thomas Jefferson University, Philadelphia, PA; Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; Proteomics Resource Center, Rockefeller University, New York, NY
| | - H Deng
- Thomas Jefferson University, Philadelphia, PA; Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; Proteomics Resource Center, Rockefeller University, New York, NY
| | - MP Lisanti
- Thomas Jefferson University, Philadelphia, PA; Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; Proteomics Resource Center, Rockefeller University, New York, NY
| | - C Wang
- Thomas Jefferson University, Philadelphia, PA; Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; Proteomics Resource Center, Rockefeller University, New York, NY
| |
Collapse
|
25
|
Girondo MA, Peck AR, Freydin B, Chervoneva I, Hyslop T, Kovatich AJ, Hooke JA, Shriver CD, Mitchell EP, Rui H. Abstract P1-08-20: Increased risk of hormone therapy failure in breast cancers expressing low phospho-Stat5: Validation of quantitative immunofluorescence assay parameters. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p1-08-20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Previous analyses of three breast cancer cohorts revealed that loss of phospho-Stat5 in breast cancer is associated with significantly elevated risk of hormone therapy failure (1, 2). Nuclear localized tyrosine phosphorylated Stat5 (Nuc-pYStat5) may therefore have clinical value as a predictive marker. Analysis of two of the three previously reported anti-estrogen treated patient cohorts used pathologist scoring of diaminobenzidine (DAB) chromogen-stained Stat5. However the third cohort, analyzed by quantitative immunofluorescence analysis (QIF) on the Genoptix/HistoRx AQUA platform, revealed a greater hazard ratio than the cohorts analyzed by pathologist DAB-scoring. To extend and validate these observations, we applied the Nuc-pYStat5 cutpoint derived in our previous study (2) to an independent cohort of anti-estrogen-treated breast cancer patients using two distinct QIF software platforms, AQUA and Definiens Tissue Studio. Tissue Studio relies on supervised machine learning and multiparametric features of a high-resolution whole slide image to identify cancer cell regions, while AQUA software relies on costaining of a tumor marker to identify cancer cell regions. The two QIF platforms produced highly concordant Nuc-pYStat5 levels (R2 linear = 0.96, P<0.001, N = 344) and confirmed a significant elevated risk of failing antiestrogen therapy in patients whose tumors had lost Nuc-pYStat5 (Hazard ratio 3.6; 95% CI 1.8-7.4; P<0.02; N = 98). On both QIF platforms, Nuc-pYStat5 remained an independent marker after multivariate adjustment for standard pathology parameters, including ER/PR, HER2, age, node status and grade, with a hazard ratio of 5.8 (95% CI 1.3-22.2; P = 0.02; N = 52). High concordance between Nuc-pYStat5 levels produced by the two QIF platforms held up in a second independent dataset of more than 300 breast cancer specimens (R2 linear = 0.97, P<0.001, N = 382). Nuc-pYStat5 levels by the two QIF methods remained highly concordant across the entire dynamic range in both patient cohorts. Furthermore, high concordance was also observed between replicate QIF analyses of Nuc-pYStat5 on serial tumor microarray sections stained in the same run on an automated immunostainer (Concordance Correlation Coefficient (CCC) = 0.96; 95% CI 0.96-0.97). Modest inter-assay staining variation (CCC = 0.84; 95% CI 0.82-0.87) for Nuc-pYStat5 when serial tumor microarrays were stained on different runs several days apart could be corrected for by normalization procedures (CCC = 0.94; 95% CI 0.92-0.95). This progress supports the utility of QIF analysis of Nuc-pYStat5 levels in human breast cancer and further documents the potential value of Nuc-pYStat5 as a predictive marker of response to antiestrogen therapy. The study confirms that further retrospective and prospective validation studies are warranted.
References:
1) Yamashita et al. Stat5 expression predicts response to endocrine therapy and improves survival in estrogen receptor-positive breast cancer. Endocr Relat Cancer. 2006;13:885-93.
2) Peck et al. Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure. J Clin Oncol. 2011;29:2448-58.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P1-08-20.
Collapse
Affiliation(s)
- MA Girondo
- Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; MDR Global Systems, LLC, Windber, PA; Walter Reed National Military Medical Center, Bethesda, MD
| | - AR Peck
- Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; MDR Global Systems, LLC, Windber, PA; Walter Reed National Military Medical Center, Bethesda, MD
| | - B Freydin
- Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; MDR Global Systems, LLC, Windber, PA; Walter Reed National Military Medical Center, Bethesda, MD
| | - I Chervoneva
- Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; MDR Global Systems, LLC, Windber, PA; Walter Reed National Military Medical Center, Bethesda, MD
| | - T Hyslop
- Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; MDR Global Systems, LLC, Windber, PA; Walter Reed National Military Medical Center, Bethesda, MD
| | - AJ Kovatich
- Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; MDR Global Systems, LLC, Windber, PA; Walter Reed National Military Medical Center, Bethesda, MD
| | - JA Hooke
- Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; MDR Global Systems, LLC, Windber, PA; Walter Reed National Military Medical Center, Bethesda, MD
| | - CD Shriver
- Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; MDR Global Systems, LLC, Windber, PA; Walter Reed National Military Medical Center, Bethesda, MD
| | - EP Mitchell
- Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; MDR Global Systems, LLC, Windber, PA; Walter Reed National Military Medical Center, Bethesda, MD
| | - H Rui
- Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; MDR Global Systems, LLC, Windber, PA; Walter Reed National Military Medical Center, Bethesda, MD
| |
Collapse
|
26
|
Chen Y, Kovatich AJ, Fantacone-Campbell JL, Hooke JA, Kvecher L, Kovatich AW, Gallagher CM, Hueman MT, Hyslop T, Mural RJ, Shriver CD, Rui H, Hu H. Abstract P4-06-09: HER2+ and HER2- luminal B subtypes have similar overall survival and histologic grade distributions. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p4-06-09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background There are multiple subtypes in invasive breast cancers (IBCs). Immunohistochemistry (IHC)-based assays using ER, PR, HER2, and Ki67 for subtyping has been developed. However, association between such subtypes and treatment outcomes and histology is not completely known, and are impacted by dataset-to-dataset and pathologist-to-pathologist variations. We report an analysis on these problems, as a pilot study of a project involving 5,000 patients and 250 protein biomarkers.
Methods Patients were enrolled for the Clinical Breast Care Project from a military site with data collected per IRB-approved protocols, from 2000 to 2010. Total of 215 female IBC cases were included in this study, with surgically resected tumors (SRT) assayed for ER, PR, HER2, and Ki67 by IHC in a central CLIA-certified lab following clinical guidelines where applicable. All slides were reviewed by a single experienced breast pathologist. ER and PR was positive if nuclear staining was >5%. HER2 was negative if IHC = 0 or 1+ and positive if IHC = 3+; For IHC = 2+, the FISH result determined the final call. Ki67 was positive if nuclear staining was > = 15%. For IBC subtypes, LA was ER+/HER2-/Ki67-; Two LB subtypes were defined, with LB1 being ER+/HER2-/Ki67+ and LB2 being ER+/HER2+; Her2+ was ER-/PR-/HER2+; TN was ER-/PR-/HER2-. Statistical analyses were performed using SAS, Kaplan-Meier estimate and log-rank test were used for survival analysis and the follow-up period was 10 years with a median of 4.6 years. Chi-Square test was used for categorical data analysis supplemented by Fisher's Exact test as appropriate.
Results 204 of the 215 cases were classified into subtypes of LA (n = 74, 7 deceased), LB1 (n = 53, 4 deceased), LB2 (n = 14, 1 deceased), Her2+ (n = 14, 1 deceased), and TN (n = 49, 16 deceased). Despite the low number of events in some subtypes, there was a significant difference in overall survival between the 5 subtypes of IBCs defined here (p = 0.0023), with TN cases showing the least favorable outcome. No difference was observed in outcome between LB1 and LB2 (p = 0.86). Overall, Ki67+ cases trended toward worse outcomes (p = 0.08), which was also observed in TN (p = 0.17) but not other subtypes. Histologic grades were significantly different among the 5 subtypes (p = 6.25E-20); 96% of LA cases were G1 or G2, over 80% of LB1 and LB2 cases were G2 or G3, and all Her2+ and 93% of TN cases were G2 or G3. Within the luminal subtypes, grade distribution for LA cases was significantly different from that for LB cases (p<0.0001) but there was no difference between LB1 and LB2 cases (p = 0.95).
Discussion In this cohort where all IHC and pathology slides were reviewed by a single pathologist, we used cell proliferation marker Ki67 to help classify luminal IBCs into LA, LB1 (HER2-), and LB2 (HER2+). Overall survival analysis result for all cases was consistent with the literature, Ki67+ cases trended toward worse outcomes, and no outcome difference was identified between LB1 and LB2. Histologic grade distributions in different subtypes were consistent with the literature; we further found no difference between LB1 and LB2 subtypes.
The views expressed in this abstract are those of the authors and do not reflect the official policy of the Department of Defense, or US Government.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P4-06-09.
Collapse
Affiliation(s)
- Y Chen
- Biomedical Informatics, Windber Research Institute, Windber, PA; Clinical Breast Care Project, Walter Reed National Military Medical Center, Bethesda, MD; MDR Global Systems, Windber, PA; Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA
| | - AJ Kovatich
- Biomedical Informatics, Windber Research Institute, Windber, PA; Clinical Breast Care Project, Walter Reed National Military Medical Center, Bethesda, MD; MDR Global Systems, Windber, PA; Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA
| | - JL Fantacone-Campbell
- Biomedical Informatics, Windber Research Institute, Windber, PA; Clinical Breast Care Project, Walter Reed National Military Medical Center, Bethesda, MD; MDR Global Systems, Windber, PA; Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA
| | - JA Hooke
- Biomedical Informatics, Windber Research Institute, Windber, PA; Clinical Breast Care Project, Walter Reed National Military Medical Center, Bethesda, MD; MDR Global Systems, Windber, PA; Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA
| | - L Kvecher
- Biomedical Informatics, Windber Research Institute, Windber, PA; Clinical Breast Care Project, Walter Reed National Military Medical Center, Bethesda, MD; MDR Global Systems, Windber, PA; Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA
| | - AW Kovatich
- Biomedical Informatics, Windber Research Institute, Windber, PA; Clinical Breast Care Project, Walter Reed National Military Medical Center, Bethesda, MD; MDR Global Systems, Windber, PA; Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA
| | - CM Gallagher
- Biomedical Informatics, Windber Research Institute, Windber, PA; Clinical Breast Care Project, Walter Reed National Military Medical Center, Bethesda, MD; MDR Global Systems, Windber, PA; Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA
| | - MT Hueman
- Biomedical Informatics, Windber Research Institute, Windber, PA; Clinical Breast Care Project, Walter Reed National Military Medical Center, Bethesda, MD; MDR Global Systems, Windber, PA; Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA
| | - T Hyslop
- Biomedical Informatics, Windber Research Institute, Windber, PA; Clinical Breast Care Project, Walter Reed National Military Medical Center, Bethesda, MD; MDR Global Systems, Windber, PA; Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA
| | - RJ Mural
- Biomedical Informatics, Windber Research Institute, Windber, PA; Clinical Breast Care Project, Walter Reed National Military Medical Center, Bethesda, MD; MDR Global Systems, Windber, PA; Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA
| | - CD Shriver
- Biomedical Informatics, Windber Research Institute, Windber, PA; Clinical Breast Care Project, Walter Reed National Military Medical Center, Bethesda, MD; MDR Global Systems, Windber, PA; Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA
| | - H Rui
- Biomedical Informatics, Windber Research Institute, Windber, PA; Clinical Breast Care Project, Walter Reed National Military Medical Center, Bethesda, MD; MDR Global Systems, Windber, PA; Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA
| | - H Hu
- Biomedical Informatics, Windber Research Institute, Windber, PA; Clinical Breast Care Project, Walter Reed National Military Medical Center, Bethesda, MD; MDR Global Systems, Windber, PA; Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA
| |
Collapse
|
27
|
Rui H, Utama FE, Yanac AF, Xia G, Peck AR, Liu C, Rosenberg AL, Wagner KU, Yang N. Abstract S1-8: Prolactin-humanized mice: an improved animal recipient for therapy response-testing of patient-derived breast cancer xenotransplants. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-s1-8] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Eighty percent of newly diagnosed breast cancer represents estrogen receptor(ER)-positive luminal subtypes. Many patients with luminal breast cancer develop antiestrogen resistant disease. It has historically been particularly difficult to establish ER-positive breast cancer lines from primary breast cancer in the laboratory or in mice. Murine and bovine prolactins, the major lactogens in current laboratory experimental in vivo and in vitro conditions, fail to activate human prolactin receptors because of species incompatibility. In fact, murine prolactin is a potent antagonist for human prolactin receptors. Because ER-positive, luminal breast cancers also express prolactin receptors, we hypothesized that lack of human lactogenic activity under experimental conditions selected against establishment of ER-positive breast cancer in the laboratory. We therefore genetically engineered mice to express physiological levels of human prolactin in place of mouse prolactin and backcrossed the mice for ten generations into the immunodeficient NSG strain. The resulting hPRL.NSG mice have a greatly improved take rate for ER positive, luminal type of breast cancer, suggesting key tumor-promoting roles for prolactin in luminal breast cancer. A panel of novel transplantable human breast cancer lines has been established in hPrl.NSG mice, the majority of which are ER-positive. The transplantable lines maintain key histopathological characteristics and expression of major marker proteins of the primary patient tumors. Intriguingly, initial tumor establishment and growth rates of breast cancer xenografts were consistently greater in the hPrl.NSG mice than in wildtype NSG mice. Furthermore, tumors grown in hPrl.NSG were more responsive to tamoxifen than size-matched tumors grown in wildtype NSG mice. At least two new tumor lines examined so far develop spontaneous distant metastases in hPrl.NSG mice, with evidence of prolactin-dependent progression of ER-positive disease. Collectively, these observations validate the hPrl.NSG mice as an improved recipient for preclinical modeling of human breast cancer in vivo, both for therapeutic targeting of prolactin-pathways and other growth and survival pathways, as well as overcoming anti-estrogen resistance.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr S1-8.
Collapse
Affiliation(s)
- H Rui
- Thomas Jefferson University, Philadelphia, PA; Eppley Institute for Research in Cancer and Allied Diseases, Omaha, NE
| | - FE Utama
- Thomas Jefferson University, Philadelphia, PA; Eppley Institute for Research in Cancer and Allied Diseases, Omaha, NE
| | - AF Yanac
- Thomas Jefferson University, Philadelphia, PA; Eppley Institute for Research in Cancer and Allied Diseases, Omaha, NE
| | - G Xia
- Thomas Jefferson University, Philadelphia, PA; Eppley Institute for Research in Cancer and Allied Diseases, Omaha, NE
| | - AR Peck
- Thomas Jefferson University, Philadelphia, PA; Eppley Institute for Research in Cancer and Allied Diseases, Omaha, NE
| | - C Liu
- Thomas Jefferson University, Philadelphia, PA; Eppley Institute for Research in Cancer and Allied Diseases, Omaha, NE
| | - AL Rosenberg
- Thomas Jefferson University, Philadelphia, PA; Eppley Institute for Research in Cancer and Allied Diseases, Omaha, NE
| | - K-U Wagner
- Thomas Jefferson University, Philadelphia, PA; Eppley Institute for Research in Cancer and Allied Diseases, Omaha, NE
| | - N Yang
- Thomas Jefferson University, Philadelphia, PA; Eppley Institute for Research in Cancer and Allied Diseases, Omaha, NE
| |
Collapse
|
28
|
Kovatich AJ, Luo C, Chen Y, Hooke JA, Kvecher L, Rui H, Shriver CD, Mural RJ, Hu H. Abstract P2-05-21: Molecular subtypes of invasive breast cancers show differential expression of the proliferation marker Aurora Kinase A (AURKA). Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p2-05-21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Invasive breast cancer (IBC) has been classified into four major subtypes based on gene expression profiling. The luminal A subtype (LA) has the best prognosis, when compared to luminal B (LB), HER2+, and basal-like (Basal). Ki67 by gene expression or immunohistochemistry (IHC) is commonly used as a proliferation index. The function of Ki67 in proliferation remains unknown. AURKA (STK15) is known to play an important role in mitosis, and is a component of the 21-gene recurrence score of the Oncotype Dx. With multiple platforms of molecular data available from hundreds of IBC tissues in The Cancer Genome Atlas project (TCGA), we sought to study the association of AURKA with different IBC subtypes and explore its use as a proliferation marker in IBCs.
Methods: Gene expression (Agilent, log2 transformed), relative DNA copy number (CN, Affymetrix SNP 6.0), and exome sequence mutation (Illumina) data for 459 IBC cases were downloaded from the TCGA data portal. PAM50 classification results of all samples were obtained from the TCGA breast cancer AWG group and included 203 LA, 113 LB, 51 HER2+, 84 Basal-like, and 8 Normal-like which were not used in this study due to the low numbers. Kruskal-Wallis tests were used to evaluate the differences among four subtypes on AURKA expression and CN, followed by Wilcoxon Mann-Whitney test with Bonferroni adjustment for pairwise analyses. Pearson's Correlation Coefficient was used for correlation analyses. All statistical analyses were performed using SAS and R, and two-sided, p values <.05 were considered statistically significant.
Results: There was a significant difference among IBC subtypes, in gene expression as well as in CN (p values < 0.0001). AURKA mRNA levels were significantly lower in LA (mean±SD, −2.61±0.63) compared to LB (−1.45±0.78), HER2+ (−1.38±0.61), and Basal (−1.26±0.62) subtypes (p values all < 0.0001). No significant difference was detected between other subtype pairs. In CN analysis, Basal (0.09±0.22) was lower than HER2+ (0.32±0.308, p < 0.0002) and LB (0.33±0.41, p < 0.0001), and LA (0.14±0.28) is lower than HER2 (p < 0.0016) and LB (p < 0.0001), but no other significant CN difference between the subtypes were found. The means and SDs are provided for reference only. No correlation of p53 mutation status and AURKA expression were observed. However, AURKA gene expression level is correlated with MKI67 gene expression (R = 0.69, p < 2.2e−16), and its correlation with PAM50 proliferation score is even higher (R = 0.80, p < 2.2e−16).
Discussion: Using the TCGA data we observed that the mean gene expression level of AURKA is significantly lower in LA than the other IBC subtypes, by more than 50% (note the log2 transformation). This differential expression is not completely due to CN changes (especially for the Basal subtype). There is a strong association with other tumor cell proliferation markers such as the MKI67 gene and the PAM50 proliferation score. We are using computational and laboratorial studies to better understand the role of AURKA in the etiology of invasive breast cancers.
The views expressed in this article are those of the author and do not reflect the official policy of the Department of Defense, or U.S. Government.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P2-05-21.
Collapse
Affiliation(s)
- AJ Kovatich
- Windber Research Institute, Windber, PA; Walter Reed National Military Medical Center, Bethesda, MD; MDR, Global Systems LLC, Windber, PA; Thomas Jefferson University, Philadelphia, PA
| | - C Luo
- Windber Research Institute, Windber, PA; Walter Reed National Military Medical Center, Bethesda, MD; MDR, Global Systems LLC, Windber, PA; Thomas Jefferson University, Philadelphia, PA
| | - Y Chen
- Windber Research Institute, Windber, PA; Walter Reed National Military Medical Center, Bethesda, MD; MDR, Global Systems LLC, Windber, PA; Thomas Jefferson University, Philadelphia, PA
| | - JA Hooke
- Windber Research Institute, Windber, PA; Walter Reed National Military Medical Center, Bethesda, MD; MDR, Global Systems LLC, Windber, PA; Thomas Jefferson University, Philadelphia, PA
| | - L Kvecher
- Windber Research Institute, Windber, PA; Walter Reed National Military Medical Center, Bethesda, MD; MDR, Global Systems LLC, Windber, PA; Thomas Jefferson University, Philadelphia, PA
| | - H Rui
- Windber Research Institute, Windber, PA; Walter Reed National Military Medical Center, Bethesda, MD; MDR, Global Systems LLC, Windber, PA; Thomas Jefferson University, Philadelphia, PA
| | - CD Shriver
- Windber Research Institute, Windber, PA; Walter Reed National Military Medical Center, Bethesda, MD; MDR, Global Systems LLC, Windber, PA; Thomas Jefferson University, Philadelphia, PA
| | - RJ Mural
- Windber Research Institute, Windber, PA; Walter Reed National Military Medical Center, Bethesda, MD; MDR, Global Systems LLC, Windber, PA; Thomas Jefferson University, Philadelphia, PA
| | - H Hu
- Windber Research Institute, Windber, PA; Walter Reed National Military Medical Center, Bethesda, MD; MDR, Global Systems LLC, Windber, PA; Thomas Jefferson University, Philadelphia, PA
| |
Collapse
|
29
|
Chen Y, Bekhash A, Kovatich AJ, Hooke JA, Kvecher L, Mitchell EP, Rui H, Mural RJ, Shriver CD, Hu H. Abstract P5-01-07: Fibroadenomatoid changes are more prevalent in middle-aged women and have a positive association with invasive breast cancer. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p5-01-07] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The role of benign breast diseases (BBDs) in the development of invasive breast cancers (IBCs) has been studied for many years. Some BBDs have been studied comprehensively (e.g., fibrocystic changes (FCC)) while less is known about other BBDs (e.g., fiboadenomatoid changes (FAC)). FAC has been considered by some researchers as a precursor of fibroadenoma (FA). Conclusions from different studies vary, partially due to different interpretation methods and diagnostic criteria when multiple hospitals and pathologists were involved. In this study, we used subjects in the Clinical Breast Care Project (CBCP) from a military medical center where pathology slides were reviewed by a single breast pathologist to study FAC, FA, and FCC in comparison to the published literature.
Methods: Subjects were enrolled in the study following IRB-approved, HIPAA-compliant protocols. All the clinicopathologic data are available from the CBCP data warehouse (DW4TR). In the CBCP, FCC is composed of 4 components: stromal fibrosis, cysts, apocrine metaplasia, and sclerosing adenosis. Two modeling studies were performed. i) For the BBDs and IBC association study, two groups of subjects were identified: 1136 subjects diagnosed with “Benign” or “Atypical” diseases, and 619 cases diagnosed with IBCs. A logistic regression model was developed for the prediction of IBCs by the 3 BBDs and 2 well-established risk factors (RF): age (younger, <=40; middle-aged, 41–60; older, >60) and race (Caucasian, African American, Asian, and other). ii) For the RF association study with the BBDs, 6 additional RFs reported to be associated with these BBDs were identified from the literature: current use of oral contraceptives, number of live births, education, body mass index, hormonal replacement therapy, and IBC family history. These 8 RFs were used to develop a logistic regression model for each of the BBDs. The analyses were performed in SAS.
Results: In the first study, age and race were confirmed as RFs for IBCs. FAC was positively associated with IBC (OR = 3.04, 95%CI=2.06 to 4.50). FA was negatively associated with IBC, and the level of the association was stronger in women without FCC (OR = 0.15, 95%CI=0.08 to 0.28), compared to women with FCC (OR = 0.40, 95%CI=0.24 to 0.65). FCC was not significantly associated with IBC. Results from the second study indicated that, age was significantly associated with FAC (p = 0.015), specifically the middle-aged women were more likely to have FAC compared to younger women (OR = 2.03, 95%CI=1.23 to 3.34), while the older women were at a non-significantly increased risk. Trends of association with FAC were also noted for the number of live birth (p = 0.095), ethnicity (p = 0.096), and current oral contraceptive pill use (p = 0.077). The FCC model results were in general consistent with the literature, and we also confirmed that age was negatively associated with the diagnosis of FA.
Discussion: Our study was consistent with FCC findings in the literature. We observed that FAC was positively associated with IBC, whereas FA was negatively associated. Also, FAC occurred more often in middle-aged women while FAs occurrence was higher in younger women. Our results suggest that FAC and FA may be two different diseases.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P5-01-07.
Collapse
Affiliation(s)
- Y Chen
- Windber Research Institute, Windber, PA; Walter Reed National Military Medical Center, Bethesda, MD; MDR, Global Systems LLC, Windber, PA; Thomas Jefferson University, Philadelphia, PA
| | - A Bekhash
- Windber Research Institute, Windber, PA; Walter Reed National Military Medical Center, Bethesda, MD; MDR, Global Systems LLC, Windber, PA; Thomas Jefferson University, Philadelphia, PA
| | - AJ Kovatich
- Windber Research Institute, Windber, PA; Walter Reed National Military Medical Center, Bethesda, MD; MDR, Global Systems LLC, Windber, PA; Thomas Jefferson University, Philadelphia, PA
| | - JA Hooke
- Windber Research Institute, Windber, PA; Walter Reed National Military Medical Center, Bethesda, MD; MDR, Global Systems LLC, Windber, PA; Thomas Jefferson University, Philadelphia, PA
| | - L Kvecher
- Windber Research Institute, Windber, PA; Walter Reed National Military Medical Center, Bethesda, MD; MDR, Global Systems LLC, Windber, PA; Thomas Jefferson University, Philadelphia, PA
| | - EP Mitchell
- Windber Research Institute, Windber, PA; Walter Reed National Military Medical Center, Bethesda, MD; MDR, Global Systems LLC, Windber, PA; Thomas Jefferson University, Philadelphia, PA
| | - H Rui
- Windber Research Institute, Windber, PA; Walter Reed National Military Medical Center, Bethesda, MD; MDR, Global Systems LLC, Windber, PA; Thomas Jefferson University, Philadelphia, PA
| | - RJ Mural
- Windber Research Institute, Windber, PA; Walter Reed National Military Medical Center, Bethesda, MD; MDR, Global Systems LLC, Windber, PA; Thomas Jefferson University, Philadelphia, PA
| | - CD Shriver
- Windber Research Institute, Windber, PA; Walter Reed National Military Medical Center, Bethesda, MD; MDR, Global Systems LLC, Windber, PA; Thomas Jefferson University, Philadelphia, PA
| | - H Hu
- Windber Research Institute, Windber, PA; Walter Reed National Military Medical Center, Bethesda, MD; MDR, Global Systems LLC, Windber, PA; Thomas Jefferson University, Philadelphia, PA
| |
Collapse
|
30
|
Peck AR, Witkiewicz AK, Liu C, Klimowicz AC, Stringer GA, Pequignot E, Freydin B, Yang N, Tran TH, Rosenberg AL, Hooke JA, Kovatich AJ, Shriver CD, Rimm DL, Magliocco AM, Hyslop T, Rui H. P1-06-24: Nuclear Localization of Stat5a Predicts Response to Antiestrogen Therapy and Prognosis of Clinical Breast Cancer Outcome. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p1-06-24] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Nuclear-localized and tyrosine-phosphorylated Stat5 has been reported as a favorable prognostic marker and predictor of response to antiestrogen therapy in breast cancer. Phospho-Stat5 antibodies do not distinguish between phosphorylated Stat5a and the closely related Stat5b, but Stat5a is considered more critical for normal mammary development than Stat5b. The purpose of this study was to determine whether levels of nuclear-localized Stat5a protein (Nuc-Stat5a) were prognostic of clinical outcome or predictive of antiestrogen response. Stat5a was detected by traditional diaminobenzidine-chromogen immunohistochemistry (IHC) and pathologist scoring or by quantitative immunofluorescence in five archival cohorts of breast cancer. Levels of nuclear-localized Stat5a (Nuc-Stat5a) were evaluated by pathologist scoring of whole tissue sections detected by IHC or automated quantitative analysis (AQUA) of immunofluorescently-labeled tissue microarrays. Levels of Nuc-Stat5a were reduced in invasive breast cancer tissues and lymph node metastases compared to normal tissue and ductal carcinoma in situ when quantified by AQUA (Material I; n=180). Tissues from patients not treated with adjuvant therapy or treated with antiestrogen monotherapy were analyzed according to Nuc-Stat5a status for breast cancer-specific survival (CSS) and time to recurrence (TTR) using univariate and multivariate statistical models, adjusting for clinical features including tumor grade, size, lymph node and ER, PR and Her2 status. In two prognostic cohorts of node-negative breast cancer patients, low expression of Nuc-Stat5a, detected by standard IHC (Material II; n=223) or quantitative analysis (Material III; n=198), was prognostic of poor breast cancer outcome as measured by univariate and multivariate CSS (Material II/III) and TTR (Material II). CSS and TTR analysis of two independent materials of tumors from patients treated with antiestrogen monotherapy and analyzed by standard IHC (Material IV; n=73) or quantitative immunofluorescence (Material V; n=97) indicated that patients whose tumors expressed low levels of Nuc-Stat5a were at a greater than 4-fold risk of antiestrogen therapy failure when adjusted for hormone receptor status and clinical features (multivariate CSS: Material IV HR=4.3 (1.2,15.6), p=0.03; Material V HR=5.0 (1.87,13.06), p=0.001). In conclusion, loss of Nuc-Stat5a is a promising independent marker of poor breast cancer prognosis in node-negative, non-adjuvant treated breast cancer patients. Additionally, Nuc-Stat5a may be a useful clinical tool to predict tumor response to antiestrogen therapy.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P1-06-24.
Collapse
Affiliation(s)
- AR Peck
- 1Thomas Jefferson University, Philadelphia, PA; Tom Baker Cancer Center, Calgary, AB, Canada; Walter Reed Army Medical Center, Washington, DC; MDR Global Systems, LLC, Windber, PA; Yale University School of Medicine, New Haven, CT
| | - AK Witkiewicz
- 1Thomas Jefferson University, Philadelphia, PA; Tom Baker Cancer Center, Calgary, AB, Canada; Walter Reed Army Medical Center, Washington, DC; MDR Global Systems, LLC, Windber, PA; Yale University School of Medicine, New Haven, CT
| | - C Liu
- 1Thomas Jefferson University, Philadelphia, PA; Tom Baker Cancer Center, Calgary, AB, Canada; Walter Reed Army Medical Center, Washington, DC; MDR Global Systems, LLC, Windber, PA; Yale University School of Medicine, New Haven, CT
| | - AC Klimowicz
- 1Thomas Jefferson University, Philadelphia, PA; Tom Baker Cancer Center, Calgary, AB, Canada; Walter Reed Army Medical Center, Washington, DC; MDR Global Systems, LLC, Windber, PA; Yale University School of Medicine, New Haven, CT
| | - GA Stringer
- 1Thomas Jefferson University, Philadelphia, PA; Tom Baker Cancer Center, Calgary, AB, Canada; Walter Reed Army Medical Center, Washington, DC; MDR Global Systems, LLC, Windber, PA; Yale University School of Medicine, New Haven, CT
| | - E Pequignot
- 1Thomas Jefferson University, Philadelphia, PA; Tom Baker Cancer Center, Calgary, AB, Canada; Walter Reed Army Medical Center, Washington, DC; MDR Global Systems, LLC, Windber, PA; Yale University School of Medicine, New Haven, CT
| | - B Freydin
- 1Thomas Jefferson University, Philadelphia, PA; Tom Baker Cancer Center, Calgary, AB, Canada; Walter Reed Army Medical Center, Washington, DC; MDR Global Systems, LLC, Windber, PA; Yale University School of Medicine, New Haven, CT
| | - N Yang
- 1Thomas Jefferson University, Philadelphia, PA; Tom Baker Cancer Center, Calgary, AB, Canada; Walter Reed Army Medical Center, Washington, DC; MDR Global Systems, LLC, Windber, PA; Yale University School of Medicine, New Haven, CT
| | - TH Tran
- 1Thomas Jefferson University, Philadelphia, PA; Tom Baker Cancer Center, Calgary, AB, Canada; Walter Reed Army Medical Center, Washington, DC; MDR Global Systems, LLC, Windber, PA; Yale University School of Medicine, New Haven, CT
| | - AL Rosenberg
- 1Thomas Jefferson University, Philadelphia, PA; Tom Baker Cancer Center, Calgary, AB, Canada; Walter Reed Army Medical Center, Washington, DC; MDR Global Systems, LLC, Windber, PA; Yale University School of Medicine, New Haven, CT
| | - JA Hooke
- 1Thomas Jefferson University, Philadelphia, PA; Tom Baker Cancer Center, Calgary, AB, Canada; Walter Reed Army Medical Center, Washington, DC; MDR Global Systems, LLC, Windber, PA; Yale University School of Medicine, New Haven, CT
| | - AJ Kovatich
- 1Thomas Jefferson University, Philadelphia, PA; Tom Baker Cancer Center, Calgary, AB, Canada; Walter Reed Army Medical Center, Washington, DC; MDR Global Systems, LLC, Windber, PA; Yale University School of Medicine, New Haven, CT
| | - CD Shriver
- 1Thomas Jefferson University, Philadelphia, PA; Tom Baker Cancer Center, Calgary, AB, Canada; Walter Reed Army Medical Center, Washington, DC; MDR Global Systems, LLC, Windber, PA; Yale University School of Medicine, New Haven, CT
| | - DL Rimm
- 1Thomas Jefferson University, Philadelphia, PA; Tom Baker Cancer Center, Calgary, AB, Canada; Walter Reed Army Medical Center, Washington, DC; MDR Global Systems, LLC, Windber, PA; Yale University School of Medicine, New Haven, CT
| | - AM Magliocco
- 1Thomas Jefferson University, Philadelphia, PA; Tom Baker Cancer Center, Calgary, AB, Canada; Walter Reed Army Medical Center, Washington, DC; MDR Global Systems, LLC, Windber, PA; Yale University School of Medicine, New Haven, CT
| | - T Hyslop
- 1Thomas Jefferson University, Philadelphia, PA; Tom Baker Cancer Center, Calgary, AB, Canada; Walter Reed Army Medical Center, Washington, DC; MDR Global Systems, LLC, Windber, PA; Yale University School of Medicine, New Haven, CT
| | - H Rui
- 1Thomas Jefferson University, Philadelphia, PA; Tom Baker Cancer Center, Calgary, AB, Canada; Walter Reed Army Medical Center, Washington, DC; MDR Global Systems, LLC, Windber, PA; Yale University School of Medicine, New Haven, CT
| |
Collapse
|
31
|
Eberhardt JS, Hyslop T, Mitchell E, Hu H, Rui H. P5-14-12: Bayesian Belief Network Mortality Analysis of a Breast Cancer Registry Data Set. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p5-14-12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Bayesian Belief Networks have been used in medicine to evaluate clinical data and develop predictive and prognostic models. As classification models, they allow us to represent pattern complexity beyond what can be accomplished with traditional Kaplan-Meier or regression models. We sought to evaluate the use of machine-learned Bayesian Belief Networks (ml-BBNs) to develop mortality models in breast cancer and to evaluate classification performance for this method.
Methods: A set of 2,300 breast bancer cases from a tumor registry at Thomas Jefferson University were used to train ml-BBNs. The registry set was broken into cohorts for modeling by follow-up times of 1 (n=2,202), 2 (n=2,183), 3 (n=2,157), and 5 (n=2,027) years. Each cohort was then used to train a ***m1-BBN and each model was evaluated for structure. Variables were recoded into categories: biomarkers (ER, PR, Ki67, HER2, p53) as positive or negative; grading, staging, and size were broken in categories; while race was recoded into Caucasian or African-American. Income and poverty level by census tract were also included. Models were evaluated for ability to classify mortality (yes/no) within the follow-up period using 10-fold cross-validation and Receiver Operating Characteristic curves.
Results: Area Under the Curve (AUC), Positive Predictive Value (PPV), and Negative Predictive Value (NPV) were calculated for each set of cohort training models and mean values and 95% confidence intervals were calculated for mortality (yes/no) within the follow-up period. AUCs (and CIs) for 1, 2, 3, and 5 years were: 0.81 (0.70 — 0.91), 0.74 (0.69 — 0.79), 0.81 (0.77 — 0.86), 0.77 (0.74 — 0.80). PPVs for 1, 2, 3, and 5 years were: 12.3% (7.5% — 17.1%), 18.8% (15.4% — 22.1%), 18.0% (15.1% — 20.9%), 28.2% (24.7% — 31.7%). NPVs for 1, 2, 3, and 5 years were: 99.2% (98.8% — 99.7%), 97.4% (96.9% — 97.8%), 96.4% (95.1% — 97.7%), 91.7% (89.1% — 94.3%). Predictors of mortality at 1 year were Tumor Stage, at 2 years were Estrogen Receptor and Tumor Stage, and at 3 and 5 years were Diagnosis Age, Tumor Stage, Estrogen Receptor status, and Ki-67 receptor status. Discussion / Conclusion: We were able to successfully train ***m1-BBNs to estimate mortality using breast cancer registry cohorts. Cross-validation showed the models to be robust. The structure of the models can inform us how different data elements contribute to the estimate of mortality. These models can be used to calculate individual probabilities for prognostic guidance given age, staging criteria, and biomarkers. Overall 5-year mortality in the study set is 15.2%, however we can derive subject-specific mortality estimates. For example, a 43-year old Stage 3, ER-Negative, Ki-67 Negative subject has a 19.9% probability of 5-year mortality, while the same subject with positive Ki-67 has a 37.8% probability of mortality. Meanwhile, the same probabilities for a 70 year old woman are 67.0% and 59.0%, respectively.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P5-14-12.
Collapse
Affiliation(s)
- JS Eberhardt
- 1DecisionQ Corporation, Washington, DC; Thomas Jefferson University, Philadelphia, PA; Windber Research Institute, Windber, PA
| | - T Hyslop
- 1DecisionQ Corporation, Washington, DC; Thomas Jefferson University, Philadelphia, PA; Windber Research Institute, Windber, PA
| | - E Mitchell
- 1DecisionQ Corporation, Washington, DC; Thomas Jefferson University, Philadelphia, PA; Windber Research Institute, Windber, PA
| | - H Hu
- 1DecisionQ Corporation, Washington, DC; Thomas Jefferson University, Philadelphia, PA; Windber Research Institute, Windber, PA
| | - H Rui
- 1DecisionQ Corporation, Washington, DC; Thomas Jefferson University, Philadelphia, PA; Windber Research Institute, Windber, PA
| |
Collapse
|
32
|
Yang N, Utama FE, Yanac AF, Liu C, Rosenberg AL, Rui H. Xenotransplantation of surgical specimens of human breast cancer directly into genetically engineered prolactin-humanized immunodeficient mice. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.27_suppl.76] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
76 Background: Prolactin is an important hormone in mammary gland biology and is indispensible for lobulo-alveolar development during pregnancy and homeostasis during lactation. Prolactin has also been implicated in promoting proliferation, survival, and/ or differentiation of breast cancer. Importantly, murine and bovine prolactin, which are the major lactogens in current laboratory experimental conditions in vivo and in vitro, fail to effectively activate human prolactin receptors because of species incompatibility. Therefore, current established human breast cancer cell lines have been selected in the absence of human prolactin and do not represent the potential subgroup of cancers that depends on prolactin for survival or growth. Methods: In an effort to improve in vivo preclinical modeling of human breast cancer and to establish new human breast cancer lines that are prolactin-dependent or prolactin-sensitive, we used genetic-engineering to generate a human prolactin knock-in mouse line, which expresses physiological levels of human prolactin in place of mouse prolactin. We have crossed the prolactin-humanized mouse line into the immunodeficient NSG strain for effective xenotransplantation studies. Fresh surgical specimens from breast cancer patients were directly transplanted orthotopically into female mice within 2 hours of surgery. We then followed the growth of the xenograft tumors over time and retransplanted the tumors if they engrafted. Results: Our initial data suggested about a take rate of ~35% for the xenografted tumors. Estrogen receptor-positive luminal tumors usually have a very low engraftment rate in immunodeficient mice. However, we observed a relatively high rate of engraftment for luminal tumors. Conclusions: This new prolactin-humanized mouse model is highly relevant for in vivo exploration of tumor biology and drug response testing of breast cancer, especially for luminal subtypes.
Collapse
Affiliation(s)
- N. Yang
- Thomas Jefferson University, Philadelphia, PA; Department of Surgery, Thomas Jefferson University Hospital, Cherry Hill, NJ
| | - F. E. Utama
- Thomas Jefferson University, Philadelphia, PA; Department of Surgery, Thomas Jefferson University Hospital, Cherry Hill, NJ
| | - A. F. Yanac
- Thomas Jefferson University, Philadelphia, PA; Department of Surgery, Thomas Jefferson University Hospital, Cherry Hill, NJ
| | - C. Liu
- Thomas Jefferson University, Philadelphia, PA; Department of Surgery, Thomas Jefferson University Hospital, Cherry Hill, NJ
| | - A. L. Rosenberg
- Thomas Jefferson University, Philadelphia, PA; Department of Surgery, Thomas Jefferson University Hospital, Cherry Hill, NJ
| | - H. Rui
- Thomas Jefferson University, Philadelphia, PA; Department of Surgery, Thomas Jefferson University Hospital, Cherry Hill, NJ
| |
Collapse
|
33
|
Rui H, Purvis K, Gordeladze J. Sperm Adenylyl Cyclase in Young and Middle-Aged Men/Sperma-Adenylyl-Cyklase bei Jungen und Männern im mittleren Lebensalter. Andrologia 2009. [DOI: 10.1111/j.1439-0272.1989.tb02381.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
34
|
Rui H, Tran TH, Yang N, Utama FE, Witkiewicz A, Palazzo JP, Brill KL, Allen K, Rosenberg AL. High density tumor tissue arrays generated by cutting edge matrix assembly. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.22077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
35
|
Witkiewicz A, Ryder A, Neilson LM, Utama FE, Tran TH, Hyslop T, Rui H. Transcription factors Stat5a and Stat5b: Favorable prognostic markers in breast cancer. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.22071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
36
|
Wang Q, Liu Q, Ma Y, Rui H, Zhang Y. LuxO controls extracellular protease, haemolytic activities and siderophore production in fish pathogen Vibrio alginolyticus. J Appl Microbiol 2008; 103:1525-34. [PMID: 17953563 DOI: 10.1111/j.1365-2672.2007.03380.x] [Citation(s) in RCA: 56] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
AIMS To characterize the luxO gene in fish pathogen Vibrio alginolyticus MVP01 and investigate its roles in regulation of extracellular products (ECP) and siderophore production. METHODS AND RESULTS The luxO gene was cloned from V. alginolyticus MVP01. Genetic analysis revealed that it encoded a protein with high similarity to other LuxO homologues. The luxO in-frame deletion mutant and rpoN null mutant were constructed with suicide plasmids. We demonstrated that sole deletion in LuxO increased the secretion of extracellular protease and haemolytic products, but decreased siderophore production for V. alginolyticus MVP01. Mutants with null rpoN displayed significantly enhanced protease level and siderophore production while notable reduction in haemolytic activities of ECP. CONCLUSIONS Vibrio alginolyticus harbours functional luxO gene that regulates the secretion of extracellular protease and haemolytic materials as well as siderophore production in either sigma(54) dependent or independent manners. SIGNIFICANCE AND IMPACT OF THE STUDY The current study demonstrated that V. alginolyticus MVP01 produces extracellular protease and haemolytic activity material as well as siderophore, which may be characteristics of the virulence of the strain. Revelations that secretion of these products is under the regulation of LuxO and sigma(54) as well as the potential quorum sensing systems in V. alginolyticus MVP01 will expedite the understanding of vibriosis pathogenesis.
Collapse
Affiliation(s)
- Q Wang
- State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, People's Republic of China
| | | | | | | | | |
Collapse
|
37
|
Morris GJ, Topham AK, Guiles F, McCue P, Schwartz GF, Park PK, Rosenberg AL, Brill K, Rui H, Mitchell EP. Biomarker analysis by breast cancer phenotype in African-American versus Caucasian patients: Correlates with survival. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.10551] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
10551 Background: Breast carcinomas in African-American (AA) patients (pts) have poorer prognosis and higher likelihood of aggressive basal phenotype (triple negative for ER, PR, HER2) than those in Caucasian (C) patients (Carey et al, JAMA 2006, 295(21):2492; Morris et al, Breast Cancer Res Treat 2006, abstr 3055). We have additionally examined biomarker expression by phenotype in AA pts in our registry to further explain more aggressive behavior in this population. Methods: Stage, grade, ER, PR, Ki-67, HER2, and p53 expressions were compiled for breast carcinomas in 2,230 AA and C pts diagnosed between 1995–2004. Immunohistochemical markers were assayed using antibodies to the above proteins on paraffin-embedded formalin-fixed tissue. Differences in expression were analyzed by Chi- squared and Wilcoxon tests, and survival by Kaplan-Meier estimates. Results: AA pts have higher propensity for basal phenotype breast cancers (20.8% vs 10.4%, p<0.001) and lower propensity for Luminal A/B (ER+/PR+-/HER2-) phenotype (44.2% vs. 54.1%, p<0.001) as compared with C pts. Higher ki-67 proliferation index was found in AA pts (86.4% vs 78.8% in basal, p=0.3423; 37.1% vs. 26.7% in Luminal A/B p=0.0233) as compared with C pts. p53-positivity was higher in AA and C pts in all cases (p=0.0158), higher in AA pts with basal phenotype (p=0.2597), but identical in AA and C pts with luminal phenotypes (p=0.881). Survival was similar in basal phenotypes between races in all cases stage for stage, and controlled for ki-67 and p53 status, with a trend toward poorer survival among luminal phenotypes between races. Conclusions: AA pts have higher propensity for basal phenotype breast cancers than C pts, with higher ki-67 expression in both basal and luminal phenotypes, and higher p53 expression in basal phenotype, but these do not correlate with significant differences in survival by phenotype between races. As neither ki-67 index nor p53 expression can therefore solely explain differences in survival rates seen between races, molecular array studies between races and matched by phenotype are proposed. [Table: see text]
Collapse
Affiliation(s)
- G. J. Morris
- Thomas Jefferson Univ Hosp, Philadelphia, PA; Coalition of Cancer Cooperative Groups, Philadelphia, PA; Kimmel Cancer Center, Philadelphia, PA
| | - A. K. Topham
- Thomas Jefferson Univ Hosp, Philadelphia, PA; Coalition of Cancer Cooperative Groups, Philadelphia, PA; Kimmel Cancer Center, Philadelphia, PA
| | - F. Guiles
- Thomas Jefferson Univ Hosp, Philadelphia, PA; Coalition of Cancer Cooperative Groups, Philadelphia, PA; Kimmel Cancer Center, Philadelphia, PA
| | - P. McCue
- Thomas Jefferson Univ Hosp, Philadelphia, PA; Coalition of Cancer Cooperative Groups, Philadelphia, PA; Kimmel Cancer Center, Philadelphia, PA
| | - G. F. Schwartz
- Thomas Jefferson Univ Hosp, Philadelphia, PA; Coalition of Cancer Cooperative Groups, Philadelphia, PA; Kimmel Cancer Center, Philadelphia, PA
| | - P. K. Park
- Thomas Jefferson Univ Hosp, Philadelphia, PA; Coalition of Cancer Cooperative Groups, Philadelphia, PA; Kimmel Cancer Center, Philadelphia, PA
| | - A. L. Rosenberg
- Thomas Jefferson Univ Hosp, Philadelphia, PA; Coalition of Cancer Cooperative Groups, Philadelphia, PA; Kimmel Cancer Center, Philadelphia, PA
| | - K. Brill
- Thomas Jefferson Univ Hosp, Philadelphia, PA; Coalition of Cancer Cooperative Groups, Philadelphia, PA; Kimmel Cancer Center, Philadelphia, PA
| | - H. Rui
- Thomas Jefferson Univ Hosp, Philadelphia, PA; Coalition of Cancer Cooperative Groups, Philadelphia, PA; Kimmel Cancer Center, Philadelphia, PA
| | - E. P. Mitchell
- Thomas Jefferson Univ Hosp, Philadelphia, PA; Coalition of Cancer Cooperative Groups, Philadelphia, PA; Kimmel Cancer Center, Philadelphia, PA
| |
Collapse
|
38
|
Abstract
To identify cell populations directly responsive to prolactin (PRL), GH, erythropoietin, or granulocyte-colony stimulating factor within the physiological setting of an intact mammal, we combined in situ detection of hormone-activated signal transducer and activator of transcription (Stat)-5 in rats with high-throughput tissue array analysis using cutting-edge matrix assembly (CEMA). Inducible activation of Stat5a/b, as judged by levels of nuclear-localized, phosphoTyr694/699-Stat5a/b, served as an immediate and sensitive in situ marker of receptor signaling in rat tissues after injection into male and female rats of a single, receptor-saturating dose of hormone for maximal receptor activation. CEMA tissue arrays facilitated analysis of most tissues, including architecturally complex, thin-walled, and stratified tissues such as gut and skin. In 40 tissues analyzed, 35 PRL-responsive and 32 GH-responsive cell types were detected, of which 22 cell types were responsive to both hormones. Interestingly, PRL but not GH activated Stat5 in nearly all of the endocrine glands. In mammary glands, PRL activated Stat5 in a majority of luminal epithelial cells but not myoepithelial cells, stromal fibroblasts, or adipocytes, whereas GH activated Stat5 in a significant fraction of myoepithelial cells, fibroblasts, and adipocytes but only in a minority of luminal cells. Finally, the organism-wide screening revealed a yet-to-be identified erythropoietin-responsive cell type in connective tissue. CEMA tissue arrays provide cost-effective in situ analysis of large numbers of tissues. Biomarker-based identification of cell populations responsive to individual hormones may shed new light on endocrine disease as well as improve understanding of effects and side effects of hormones and drugs.
Collapse
Affiliation(s)
- M J LeBaron
- Thomas Jefferson University, Kimmel Cancer Center, Department of Cancer Biology, 233 South 10th Street, 330 BLSB, Philadelphia, PA 19107-5541, USA.
| | | | | | | |
Collapse
|
39
|
Utama FE, LeBaron MJ, Neilson LM, Sultan AS, Parlow AF, Wagner KU, Rui H. Human prolactin receptors are insensitive to mouse prolactin: implications for xenotransplant modeling of human breast cancer in mice. J Endocrinol 2006; 188:589-601. [PMID: 16522738 DOI: 10.1677/joe.1.06560] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Experimental testing of growth, metastatic progression and drug responsiveness of human breast cancer in vivo is performed in immunodeficient mice. Drug candidates need to show promise against human breast cancer in mice before being allowed into clinical trials. Breast cancer growth is under endocrine control by ovarian steroids and the pituitary peptide hormone prolactin. While it is recognized that the most relevant biologic effects of prolactin are achieved with prolactin from the matching species, the biologic efficacy of mouse prolactin for human prolactin receptors has not been recorded. Thus, it is unclear whether the mouse endocrine environment adequately reflects the hormonal environment in breast cancer patients with regard to prolactin. We now show both recombinant and natural pituitary-derived mouse prolactin to be a poor agonist for human prolactin receptors. Mouse prolactin failed to induce human prolactin receptor-mediated biologic responses of cell clustering, proliferation, gene induction and signal transduction, including activation of Stat5, Stat3, Erk1/2 and Akt pathways. Consistent data were derived from human breast cancer lines T-47D, MCF-7 and ZR-75.1, as well as human prolactin receptor-transfected COS-7 and 32D cells. Failure of mouse prolactin to activate human prolactin receptors uncovers a key deficiency of the mouse endocrine environment for human xenotransplant studies. Since most human breast cancers express prolactin receptors, human breast cancer transferred into mice is unnaturally selected for growth in the absence of circulating prolactin. The new insight raises concerns about the validity of analyzing biology and drug responsiveness of human breast cancer in existing mouse xenotransplant models.
Collapse
Affiliation(s)
- F E Utama
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, NRB E504, 3970 Reservoir Road NW, Washington, District of Columbia 20057, USA
| | | | | | | | | | | | | |
Collapse
|
40
|
Sakamoto K, Krempler A, Triplett AA, Zhu J, Rui H, Wagner KU. Essential functions of the Janus kinase 2 (Jak2) during mammary gland development and tumorigenesis. Breast Cancer Res 2005. [PMCID: PMC4233546 DOI: 10.1186/bcr1125] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
41
|
Park SH, Yamashita H, Rui H, Waxman DJ. Serine phosphorylation of GH-activated signal transducer and activator of transcription 5a (STAT5a) and STAT5b: impact on STAT5 transcriptional activity. Mol Endocrinol 2001; 15:2157-71. [PMID: 11731617 DOI: 10.1210/mend.15.12.0746] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
Signal transducer and activator of transcription 5b (STAT5b), the major liver-expressed STAT5 form, is phosphorylated on both tyrosine and serine in GH-stimulated cells. Although tyrosine phosphorylation is known to be critical for the dimerization, nuclear translocation, and activation of STAT5b DNA-binding and transcriptional activities, the effect of STAT5b serine phosphorylation is uncertain. Presently, we identify Ser730 as the site of STAT5b serine phosphorylation in GH-stimulated liver cells. We additionally show that the serine kinase inhibitor H7 partially blocks the GH-stimulated formation of (Ser,Tyr)-diphosphorylated STAT5b without inhibiting STAT5b nuclear translocation. Evaluation of the functional consequences of STAT5b serine phosphorylation by mutational analysis revealed an approximately 50% decrease in GH-stimulated luciferase reporter gene activity regulated by an isolated STAT5-binding site when STAT5b Ser730 was mutated to alanine and under conditions where STAT5 DNA-binding activity was not diminished. No decrease in GH-stimulated reporter activity was seen with the corresponding STAT5a-Ser725Ala mutant; however, a decrease in reporter activity occurred when the second established STAT5a serine phosphorylation site, serine 779, was additionally mutated to alanine. Unexpectedly, STAT5a-Ser725,779Ala and STAT5b-Ser730Ala displayed approximately 2-fold higher GH- or PRL-stimulated transcriptional activity compared with wild-type STAT5b when assayed using an intact beta-casein promoter-luciferase reporter. Finally, STAT5b-stimulated gene transcription was abolished in cells treated with H7, but in a manner unrelated to the inhibitory effects of H7 on STAT5b Ser730 phosphorylation. These findings suggest that the effects of STAT5b and STAT5a serine phosphorylation on STAT-stimulated gene transcription can be modulated by promoter context. Moreover, in the case of STAT5a, phosphorylation of serine 779, but not serine 725, may serve to regulate target gene transcriptional activity.
Collapse
Affiliation(s)
- S H Park
- Division of Cell and Molecular Biology, Department of Biology, Boston University, Boston, Massachusetts 02215, USA
| | | | | | | |
Collapse
|
42
|
Yamashita H, Nevalainen MT, Xu J, LeBaron MJ, Wagner KU, Erwin RA, Harmon JM, Hennighausen L, Kirken RA, Rui H. Role of serine phosphorylation of Stat5a in prolactin-stimulated beta-casein gene expression. Mol Cell Endocrinol 2001; 183:151-63. [PMID: 11604235 DOI: 10.1016/s0303-7207(01)00546-9] [Citation(s) in RCA: 60] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Milk production remains suppressed in mammals during late pregnancy despite high levels of lactogenic polypeptide hormones. At parturition, associated with a precipitous fall in circulating progesterone, rising glucocorticoid levels synergize with prolactin to initiate copious milk production. This synergy is mediated at least in part through the coordinated activation of glucocorticoid receptors and transcription factor Stat5, particularly Stat5a. Here we show that two proline-juxtaposed serine residues within the transactivation domain of Stat5a are phosphorylated in the mammary gland during late gestation and lactation, and that these phosphorylation sites inhibit the transcriptional activity of Stat5a in the absence of glucocorticoid receptor costimulation. Specifically, transfection assays revealed that phosphorylation of residues S725 and S779 of Stat5a cooperatively suppressed prolactin-stimulated transcription from the beta-casein promoter in both COS-7 kidney and MCF-7 mammary cells. This suppression was associated with shortened duration and reduced amplitude of nuclear DNA binding activity of wild type Stat5a relative to that of the serine phosphorylation-defective Stat5 mutant. However, costimulation of glucocorticoid receptors completely reversed the suppressive effect of Stat5a serine phosphorylation on beta-casein gene transcription. We propose that serine phosphorylation within the transactivation domain may limit the activity of Stat5a in the absence of proper coactivation by glucocorticoid receptors.
Collapse
Affiliation(s)
- H Yamashita
- United States Military Cancer Institute, Department of Pathology, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Abstract
Glycyrrhiza pallidiflora hairy roots were induced from axenic young plants by direct infection with Agrobacterium rhizogenes. The chemical constituents were then investigated after mass culture. The isoflavone, licoagroisoflavone and the coumestan, licoagroside C, were isolated along with seven known flavonoids. Their structures were determined on the basis of spectroscopic evidence.
Collapse
Affiliation(s)
- W Li
- School of Pharmaceutical Sciences, Toho University, 2-2-1 Miyama, Funabashi-city, 274-8510, Chiba, Japan
| | | | | | | | | | | | | |
Collapse
|
44
|
Kirken RA, Erwin RA, Wang L, Wang Y, Rui H, Farrar WL. Functional uncoupling of the Janus kinase 3-Stat5 pathway in malignant growth of human T cell leukemia virus type 1-transformed human T cells. J Immunol 2000; 165:5097-104. [PMID: 11046040 DOI: 10.4049/jimmunol.165.9.5097] [Citation(s) in RCA: 41] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Human T cell leukemia virus type 1 (HTLV-1) transforms cytokine-dependent T lymphocytes and causes adult T cell leukemia. Janus tyrosine kinase (Jak)3 and transcription factors Stat5a and Stat5b are essential for the proliferation of normal T cells and are constitutively hyperactivated in both HTLV-1-transformed human T cell lines and lymphocytes isolated from HTLV-1-infected patients; therefore, a critical role for the Jak3-Stat5 pathway in the progression of this disease has been postulated. We recently reported that tyrphostin AG-490 selectively blocked IL-2 activation of Jak3/Stat5 and growth of murine T cell lines. Here we demonstrate that disruption of Jak3/Stat5a/b signaling with AG-490 (50 microM) blocked the proliferation of primary human T lymphocytes, but paradoxically failed to inhibit the proliferation of HTLV-1-transformed human T cell lines, HuT-102 and MT-2. Structural homologues of AG-490 also inhibited the proliferation of primary human T cells, but not HTLV-1-infected cells. Disruption of constitutive Jak3/Stat5 activation by AG-490 was demonstrated by inhibition of 1) tyrosine phosphorylation of Jak3, Stat5a (Tyr(694)), and Stat5b (Tyr(699)); 2) serine phosphorylation of Stat5a (Ser(726)) as determined by a novel phosphospecific Ab; and 3) Stat5a/b DNA binding to the Stat5-responsive beta-casein promoter. In contrast, AG-490 had no effect on DNA binding by p50/p65 components of NF-kappaB, a transcription factor activated by the HTLV-1-encoded phosphoprotein, Tax. Collectively, these data suggest that the Jak3-Stat5 pathway in HTLV-1-transformed T cells has become functionally redundant for proliferation. Reversal of this functional uncoupling may be required before Jak3/Stat5 inhibitors will be useful in the treatment of this malignancy.
Collapse
Affiliation(s)
- R A Kirken
- Department of Integrative Biology and Pharmacology, University of Texas Health Science Center, Houston, TX 77030, USA.
| | | | | | | | | | | |
Collapse
|
45
|
Nevalainen MT, Ahonen TJ, Yamashita H, Chandrashekar V, Bartke A, Grimley PM, Robinson GW, Hennighausen L, Rui H. Epithelial defect in prostates of Stat5a-null mice. J Transl Med 2000; 80:993-1006. [PMID: 10908145 DOI: 10.1038/labinvest.3780105] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
The transcription factor Stat5a critically mediates prolactin (PRL)-induced mammary gland development and lactogenesis. PRL also stimulates growth and differentiation of prostate tissue. Specifically, hyperprolactinemia gives rise to prostate hyperplasia, and prostate size is reduced in PRL-deficient mice. We therefore investigated the importance of Stat5a for prostate development and function by examining Stat5a-null mice. The absence of Stat5a in mice was associated with a distinct prostate morphology characterized by an increased prevalence of local disorganization within acinar epithelium of ventral prostates. Affected acini were typically filled with desquamated, granular epithelial cells that had become embedded in dense, coagulated secretory material. These features were reminiscent of acinar cyst formation and degeneration frequently observed in human benign prostate hyperplasia, however, cystic changes in prostate acini of Stat5a-deficient mice were not associated with increased prostate size or morphologic hallmarks of epithelial hyperplasia. Instead, immunohistochemistry of the prostate-specific secretory marker, probasin, suggested that hypersecretory function of the epithelium could underlie local congestion and cyst formation in prostates of Stat5a-null mice. Serum testosterone and PRL levels were normal in Stat5a knockout mice, but prostate PRL receptor expression was reduced as determined by immunohistochemistry. Expression levels or activation states of other PRL signal transduction proteins, including Stat5b, Stat3, Stat1, ERK1, and ERK2 were not altered. The present study offers the first evidence for a direct role of Stat5a in the maintenance of normal tissue architecture and function of the mouse prostate.
Collapse
Affiliation(s)
- M T Nevalainen
- Department of Pathology, Uniformed Services University of the Health Sciences, and National Institutes of Diabetes and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Ahonen TJ, Härkönen PL, Laine J, Rui H, Martikainen PM, Nevalainen MT. Prolactin is a survival factor for androgen-deprived rat dorsal and lateral prostate epithelium in organ culture. Endocrinology 1999; 140:5412-21. [PMID: 10537173 DOI: 10.1210/endo.140.11.7090] [Citation(s) in RCA: 62] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
PRL is one of several polypeptide factors that regulate growth and differentiation of prostate epithelium besides steroid hormones. This hormone may also participate in the development of pathologic changes of the prostate, as evidenced by marked prostate hyperplasia in hyperprolactinemic mice. We have previously demonstrated expression of PRL receptors and androgen-dependent local production of PRL in rat and human prostate epithelium, suggesting the existence of an autocrine loop. We now show that PRL acts as a survival factor for epithelial cells of rat dorsal and lateral prostate but not ventral prostate, using long-term organ cultures as an in vitro model. Culture of prostate explants in androgen-free medium was associated with a transient surge of apoptosis during the first 2-4 days of culture in rat ventral, dorsal, and lateral prostate tissues, as quantified by either nuclear morphology or in situ DNA fragmentation analysis. PRL significantly inhibited apoptosis in androgen-deprived dorsal and lateral prostate cultures, by 40-60%, as determined by the two methods. The present study has established conditions and methodology for analysis of apoptosis in organ cultures of rat prostate and suggests a physiological role for PRL as a survival factor for prostate epithelium.
Collapse
Affiliation(s)
- T J Ahonen
- Institute of Biomedicine, Department of Anatomy, University of Turku, Finland
| | | | | | | | | | | |
Collapse
|
47
|
Abstract
Stat5a and Stat5b are discretely encoded transcription factors that mediate signals for a broad spectrum of cytokines. Their activation is often an integral component of redundant cytokine signal cascades involving complex cross-talk and pleiotropic gene regulation by Stat5 has been implicated in cellular functions of proliferation, differentiation and apoptosis with relevance to processes of hematopoiesis and immunoregulation, reproduction, and lipid metabolism. Although Stat5a and Stat5b show peptide sequence similarities of > 90%, targeted gene disruptions in mice yield distinctive phenotypes. Prolactin-directed mammary gland maturation fails without functional Stat5a, while disruption of Stat5b in males mitigates growth hormone effects on hepatic function and body mass. The molecular basis for this biologic dichotomy is probably multifaceted. Limited structural dissimilarities between the Stat5a and Stat5b transactivation domains, or subtle differences in the DNA-binding affinities of Stat5 dimer pairs undoubtedly influence gene regulation, but cell-dependent asymmetries in availability of phosphorylated Stat5 can be an underlying factor. Differences in serine phosphorylation(s) of Stat5a and Stat5b, or Stat5 associations with adaptor proteins or co-transcription factors are other potential sources of functional disparity and the signal amplitude, frequency or duration also can be significant. In addition to Stat5 signal attenuation by phosphatase actions or classical feedback inhibition, truncated forms of Stat5 lacking in transactivation capacity may compete upstream for activation and diminish access of full length molecules to DNA binding sites.
Collapse
Affiliation(s)
- P M Grimley
- Department of Pathology, F. Edward Hebert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20854, USA
| | | | | |
Collapse
|
48
|
Abstract
Cytokines and hormones activate a network of intracellular signaling pathways to regulate cell division, survival and differentiation. In parallel, a series of growth inhibitory mechanisms critically restrict cell population sizes. For example, mitogens can be opposed in crowded cell cultures through contact-inhibition or by autocrine release of antiproliferative substances. Here, we characterize a small, heat-stable growth inhibitor secreted by a rat T lymphoma line when cultured at high cell density. Short term incubation (<60 min) of prolactin-responsive Nb2 lymphoma cells at high density selectively blocked prolactin stimulation of p42/p44 mitogen-activated protein kinases and transcription factors Stat1 and Stat3 but not prolactin activation of Stat5 or the tyrosine kinase Jak2. The selective effects of cell density on prolactin signaling were reversible. Furthermore, exposure of cells at low density to conditioned media from cells incubated at high density had the same inhibitory effects on prolactin signaling. This selective inhibition of discrete prolactin signals was mimicked by short term preincubation of cells at low density with staurosporine or genistein but not with bis-indoleyl maleimide, cyclic nucleotide analogs, calcium ionophore A23187, or phorbol 12-myristate 13-acetate. A heat-stable, proteinase K-resistant, low molecular weight factor with these characteristics was recovered from high density culture medium. The partially purified inhibitor suppressed Nb2 cell growth with a sigmoidal concentration response consistent with a saturable, receptor-mediated process.
Collapse
Affiliation(s)
- H Yamashita
- Department of Pathology, Uniformed Services University of the Health Sciences School of Medicine, Bethesda, Maryland 20814, USA
| | | | | | | | | |
Collapse
|
49
|
Xiaoguang C, Hongyan L, Xiaohong L, Yan L, Rui H. The effects of S-3-1 on lipid peroxidation and scavenging free radicals in vitro. Chin Med Sci J 1999; 14:38-40. [PMID: 12899382] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 03/04/2023]
Abstract
S-3-1 is a simplified synthetic analogue of the active principle of Salvia miltiorrhioza. Electron spin resonance spectrometry using 5,5'-dimethyl-1-pyrroline-N-oxide as a scavenger of free radicals indicated that 200 microg/ml of S-3-1 scavenged 1,1-diphenyl-2-picrylhydrazyl radicals completely. 25 microg/ml of this compound quenched 100% of superoxide anion and a concentration of 250 microg/ml of S-3-1 quenched 63% of hydroxyl radicals. It was also shown that 3.56 mg/ml of S-3-1 could inhibit lipid peroxidation in microsome fraction from rat liver induced by FeSO4 and cysteine. These results show that S-3-1 is an effective antioxidant by scavenging free radicals.
Collapse
Affiliation(s)
- C Xiaoguang
- Department of Pharmacology, Institute of Materia Medica, CAMS & PUMC, Beijing 100050
| | | | | | | | | |
Collapse
|
50
|
Yamashita H, Xu J, Erwin RA, Farrar WL, Kirken RA, Rui H. Differential control of the phosphorylation state of proline-juxtaposed serine residues Ser725 of Stat5a and Ser730 of Stat5b in prolactin-sensitive cells. J Biol Chem 1998; 273:30218-24. [PMID: 9804779 DOI: 10.1074/jbc.273.46.30218] [Citation(s) in RCA: 118] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Transcription factors of the Stat family are controlled by protein kinases. Phosphorylation of a positionally conserved tyrosine residue is obligatory for Stat dimerization, nuclear translocation, and specific DNA binding. Studies of Stat1 and Stat3 have suggested that serine phosphorylation may also regulate function. We now identify serine residues located in a conserved PSP motif of Stat5a (Ser725) and Stat5b (Ser730) as major phosphorylation sites, using mutagenesis, phosphoamino acid analysis, and site-specific anti-Stat5-phosphoserine antibodies. Unexpectedly, phosphorylation control of this PSP motif differed between the highly homologous Stat5a and Stat5b proteins. Whereas Ser725 of Stat5a was constitutively phosphorylated both in COS-7 cells and Nb2 lymphocytes, phosphorylation of Ser730 of Stat5b was markedly stimulated by prolactin. The data also suggested the existence of a second major serine phosphorylation site in Stat5a. Interestingly, constitutive phosphorylation of the PSP motif was suppressed by PD98059 but not by staurosporine under conditions in which both agents inhibited mitogen-activated protein kinases. Furthermore, pretreatment of cells with staurosporine, PD98059, H7, or wortmannin did not prevent either Stat5a or Stat5b from becoming maximally serine-phosphorylated after prolactin exposure. We propose that two pathways regulate Stat5 serine phosphorylation, one that is prolactin-activated and PD98059-resistant and one that is constitutively active and PD98059-sensitive and preferentially targets Stat5a. Finally, phosphorylation of the PSP motif of Stat5a or Stat5b was not essential for DNA binding or transcriptional activation of a beta-casein reporter gene in COS-7 cells, suggesting that serine kinase control of Stat5 activity differs from that of Stat1 and Stat3.
Collapse
Affiliation(s)
- H Yamashita
- Department of Pathology, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814, USA
| | | | | | | | | | | |
Collapse
|